0000850261
false
0000850261
2023-09-20
2023-09-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): September 26, 2023 (September 20, 2023)
SORRENTO THERAPEUTICS, INC.
(Exact Name of Registrant as Specified
in its Charter)
Delaware |
|
001-36150 |
|
33-0344842 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
4955 Directors Place
San Diego, CA 92121
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number,
including area code: (858) 203-4100
N/A
(Former Name, or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
Common Stock, $0.0001 par value |
|
SRNEQ |
|
N/A |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01. Entry into a Material Definitive Agreement.
Background
As previously disclosed, on
February 13, 2023, Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) and its
wholly owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (together with the Company, the “Debtors”),
commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”)
in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). The Debtors’
Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al., Case Number 23-90085
(DRJ) (the “Chapter 11 Cases”). The Debtors continue to operate their business in the ordinary course and
in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court.
As previously disclosed, and
as stated in the final order of the Bankruptcy Court on April 14, 2023, the Debtors have been conducting a dual-track (i) financing process
for the potential raising of debt, equity or hybrid financing or consummation of a restructuring transaction through a chapter 11 plan
of reorganization and (ii) marketing process for the sale or disposition of all or any portion of the Debtors’ assets under section
363 of the Bankruptcy Code, including (x) the Debtors’ equity interests in its non-debtor subsidiaries, including, but not limited
to, Scilex Holding Company (“Scilex”) and (y) the Debtors’ other assets.
As previously disclosed, on
July 5, 2023, the Debtors executed, and the Bankruptcy Court entered an interim order (the “Interim DIP Order”)
approving, that certain Debtor-in-Possession Term Loan Facility Summary of Terms and Conditions with Scilex, pursuant to which Scilex
provided the Debtors with a non-amortizing super-priority junior secured term loan facility (the “Junior DIP Facility”)
in an aggregate principal amount not to exceed the sum of (i) $20,000,000 (the “Base Amount”), plus (ii) the
amount of the commitment fee and the funding fee, each equal to 1% of the Base Amount, plus (iii) the amount of the DIP Lender Holdback
(as defined in the Interim DIP Order). The Bankruptcy Court entered a final order approving the Junior DIP Facility on July 27, 2023.
As previously disclosed, Oramed
Pharmaceuticals Inc. (“Oramed”) agreed and, after a hearing before the Bankruptcy Court on August 7, 2023, the
Bankruptcy Court approved, pursuant to definitive financing documentation entered into on August 9, 2023, to provide a non-amortizing
super-priority senior secured debtor-in-possession term loan facility (the “Senior DIP Facility”) in an aggregate
principal amount of $100,000,000, which amount was subsequently drawn in full by the Debtors.
As previously disclosed, pursuant
to a Stock Purchase Agreement, dated August 7, 2023 (as amended by that certain First Amendment to Stock Purchase Agreement, dated August
9, 2023, and that certain Second Amendment to Stock Purchase Agreement, dated August 21, 2023, the “Oramed SPA”),
Oramed agreed to buy, and Sorrento agreed to sell for a purchase price of $105 million (which purchase price consisted of a credit bid
on a dollar-for-dollar basis in respect of the full amount of outstanding obligations under the Senior DIP Facility as of the closing
date of the sale, with the remaining balance to be paid in cash to Sorrento), following the conclusion of the auction that commenced on
August 14, 2023 (the “Auction”), the following: (A) all of the shares of the common stock, par value $0.0001
per share, of Scilex (the “Scilex Common Shares”) held by Sorrento (other than any Scilex Common Shares held
in abeyance by Sorrento on behalf of certain warrantholders of Sorrento); (B) all of the issued and outstanding shares of Series A preferred
stock of Scilex (the “Scilex Preferred Shares”) held by Sorrento, less one Scilex Preferred Share that was to
be retained by Sorrento; and (C) certain warrants for the purchase of Scilex Common Shares (the “Scilex Warrants”)
held by Sorrento. The sale contemplated under the Oramed SPA did not close and has been terminated pursuant to the Termination Agreement
(as defined below) as described further herein.
As previously disclosed, on
September 11, 2023, Scilex, Oramed and Sorrento executed non-binding term sheets relating to, among other things, (i) the Securities Transfer
(as defined below) (the “Securities Transfer Term Sheet”) (which the official committee of unsecured creditors
and the official committee of equity security holders in the Chapter 11 Cases each signed as “Consenting Parties” thereto)
and (ii) the senior secured note to be issued by Scilex to Oramed (such term sheets, collectively, the “Scilex Term Sheets”)
providing for, among other things (as set forth below), the Securities Transfer, the assumption by Scilex of the Debtors’ obligations
under the Senior DIP Facility (the “Senior DIP Assumption”) and the termination of the Oramed SPA, in each case,
subject to entry into definitive documentation relating thereto. After a hearing before the Bankruptcy Court on September 12, 2023, the
Bankruptcy Court entered a final order (the “Final Sale Order”) approving the Scilex Term Sheets.
The Scilex SPA
On September 21, 2023, as
contemplated by the Scilex Term Sheets, Sorrento and Scilex entered into that certain Stock Purchase Agreement (the “Scilex
SPA”) and simultaneously consummated the Securities Transfer pursuant thereto (the “Closing”).
Pursuant to the terms of the
Scilex SPA, on September 21, 2023, Scilex acquired all of the Scilex Common Shares owned by Sorrento (other than 1,917,210 Scilex Common
Shares held in abeyance by Sorrento on behalf of certain warrantholders of Sorrento), (ii) all of the Scilex Preferred Shares owned by
Sorrento and (iii) all of the Scilex Warrants owned by Sorrento ((i) through (iii) above, collectively, the “Transfer Securities”
and such acquisition by Scilex, the “Securities Transfer”) for aggregate consideration consisting of: (i) $110
million, paid as follows: (x) $5 million in cash that was paid on September 14, 2023, (y) the assumption by Scilex pursuant to the Senior
DIP Assumption Agreement (as defined below) of the approximately $100 million of the Debtors’ obligations under the Senior DIP Facility
(the “Senior DIP Assumption”) and (z) $5 million in cash that was paid upon the Closing; plus (ii) the assumption
by Scilex at the Closing of certain obligations of Sorrento for legal fees and expenses in the amount of approximately $12.25 million;
plus (iii) a credit bid of approximately $23 million, representing all amounts owed to Scilex under the Junior DIP Facility, effective
as of the Closing.
The Scilex SPA contains customary
representations and warranties and covenants. Sorrento also covenants in the Scilex SPA to provide certain transition services to Scilex
for up to 120 days following the Closing, such services to be substantially similar in all material respects to the services Sorrento
has historically provided to Scilex, on the same terms and conditions (including cost) in all material respects (subject to certain terms
and limitations set forth in the Scilex SPA).
Following the Securities Transfer,
Sorrento now holds 1,917,210 Scilex Common Shares held in abeyance by Sorrento on behalf of certain warrantholders of Sorrento and no
longer has a controlling interest over Scilex. As a result, Scilex ceased to be a majority-owned subsidiary of Sorrento. Consequently,
we expect Scilex will be deconsolidated from Sorrento’s financial statements and will be presented retrospectively as discontinued
operations.
The Termination Agreement
On September 21, 2023, as
contemplated by the Scilex Term Sheets, Sorrento and Oramed entered into that certain Mutual Termination and Release Agreement (the “Termination
Agreement”), which terminated the Oramed SPA. The Termination Agreement contains a mutual release between Oramed (on the
one hand) and the Debtors and Scilex (on the other hand) in connection with all matters related to the Oramed SPA and the Chapter 11 Cases.
The Senior
DIP Assumption Agreement
On September 21, 2023, as
contemplated by the Scilex Term Sheets, Scilex, Oramed and the Debtors entered into that certain Assignment, Assumption and Release Agreement
(the “Senior DIP Assumption Agreement”) effectuating the Senior DIP Assumption. The Senior DIP Assumption Agreement
contains a mutual release in accordance with, and to the fullest extent set forth in, the Final Sale Order.
General
The foregoing summaries of
the Scilex SPA, the Termination Agreement and the Senior DIP Assumption Agreement are qualified in their entirety by reference to the
full text of such agreements. Copies of the Scilex SPA, the Termination Agreement and the Senior DIP Assumption Agreement are attached
to this Current Report on Form 8-K as Exhibit 2.1, Exhibit 2.2 and Exhibit 10.1, respectively, and are incorporated by reference herein.
Additional information about
the Chapter 11 Cases, including access to copies of the Final Order, the Scilex Term Sheets and other documents filed with the Bankruptcy
Court, is available online at https://cases.stretto.com/sorrento, a website administered by Stretto, a third-party bankruptcy claims
and noticing agent. The information on that website is not incorporated by reference into, and does not constitute part of, this Current
Report on Form 8-K.
Item 1.02. Termination of a Material
Definitive Agreement.
On September 21, 2023, Sorrento
and Oramed entered into the Termination Agreement, which terminated the Oramed SPA. The information set forth above in Item 1.01 of this
Current Report on Form 8-K relating to the Termination Agreement is incorporated herein by reference. Sorrento and Scilex were parties
to that certain Stockholder Agreement, dated as of September 12, 2022 (the “Stockholder Agreement”), pursuant
to which Sorrento had certain preferential contractual rights as a holder of Scilex Preferred Shares. The Final Sale Order approved,
among other things, the termination of the Stockholder Agreement upon the closing of the transactions described in Item 1.01. Accordingly,
the Stockholder Agreement terminated at the Closing as well.
Item 2.01. Completion of Acquisition
or Disposition of Assets.
On September 21, 2023, the
Company completed the disposition of the Transfer Securities to Scilex on the terms contemplated by the Scilex SPA. Prior to the closing
of such Securities Transfer, Sorrento held a controlling interest in Scilex. The terms of the Securities Transfer were determined following
an extensive marketing process and, ultimately, the completion of the Auction on the basis of the Oramed SPA serving as a stalking-horse
bid. The information set forth above in Item 1.01 of this Current Report on Form 8-K relating to the Securities Transfer is incorporated
herein by reference. The pro forma financial information required to be filed by Item 9.01(b) of Form 8-K is included as Exhibit 99.1
to this Current Report.
Item 7.01 Regulation FD Disclosure.
In connection with the transactions
described above, the Company issued a press release on September 22, 2023, a copy of which is attached to this Current Report on Form
8-K as Exhibit 99.2. The information under this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2 is being furnished
and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except
as shall be expressly set forth by specific reference in such a filing. This report will not be deemed an admission as to the materiality
of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 8.01. Other Events.
On September 20, 2023, Sorrento
completed a reduction in U.S. headcount from 215 to 128.
Cautionary Statement Concerning Forward-Looking
Statements
This Current Report on Form
8-K includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions
under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words
such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,”
“seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future
events or trends or that are not statements of historical matters. Forward-looking statements include statements regarding the Securities
Transfer and the anticipated accounting treatment resulting from the Securities Transfer. The Company’s actual results or outcomes
and the timing of certain events may differ significantly from those discussed in any forward-looking statements. These statements are
based on various assumptions and on the current expectations of the Company’s management and are not predictions of actual performance.
These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied
on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.
Actual events and circumstances
are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of
the Company. These forward-looking statements are subject to a number of risks and uncertainties, including risks associated with the
ability of the Company to use any proceeds from the Securities Transfer efficiently in support of its business; the Company’s ability
to obtain exit financing and to pursue a plan of reorganization and exit the Chapter 11 Cases; determinations relating to the accounting
treatment for the Securities Transfer and the deconsolidation of Scilex; and those factors discussed in the Company’s Annual Report
on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange
Commission (the “SEC”) in each case under the heading “Risk Factors,” and other documents of the
Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. There may be additional risks that the Company presently does not know or
that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking
statements. In addition, forward-looking statements reflect the Company’s expectations, plans or forecasts of future events and
views as of the date of this document. The Company anticipates that subsequent events and developments will cause its assessments to change.
However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s assessments
as of any date subsequent to the date of this document. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
104 |
Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |
* Certain schedules, exhibits and similar attachments to this
agreement have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted exhibit or other attachment will
be furnished supplementally to the SEC upon request.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SORRENTO THERAPEUTICS, INC. |
|
|
|
Date: September 26, 2023 |
By: |
/s/ Mohsin Y. Meghji |
|
|
Name: Mohsin Y. Meghji |
|
|
Title: Chief Restructuring Officer |
Exhibit 2.1
STOCK PURCHASE AGREEMENT
BY AND BETWEEN
SCILEX HOLDING COMPANY
AND
SORRENTO THERAPEUTICS, INC.
September 21, 2023
STOCK PURCHASE AGREEMENT
THIS STOCK PURCHASE AGREEMENT
is made and entered into as of September 21, 2023 (this “Agreement”), by and between Scilex Holding Company,
a Delaware corporation (the “Purchaser”) and Sorrento Therapeutics, Inc., a Delaware corporation (the “Seller”).
Purchaser and the Seller are sometimes individually referred to in this Agreement as a “Party” and collectively as
the “Parties.”
RECITALS:
WHEREAS, on February
13, 2023, the Seller and its wholly owned Subsidiary, Scintilla Pharmaceuticals, Inc. (“Scintilla”), commenced voluntary
proceedings under Chapter 11 of the Bankruptcy Code in the Bankruptcy Court, which are being jointly administered under the caption In
re Sorrento Therapeutics, Inc., et al.;
WHEREAS, on July 28,
2023, the Seller and Scintilla, as borrowers (in such capacity, the “Borrowers”), entered into that certain Junior
Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement (the “Junior DIP Loan Agreement”) with the
Purchaser, as lender (in such capacity, the “Junior DIP Lender”), pursuant to which the Borrowers obtained $20,000,000
of junior post-petition financing (the “Junior DIP Facility”);
WHEREAS, the Seller
desires to sell, convey, transfer, assign and deliver to the Purchaser, and the Purchaser desires to purchase and acquire from the Seller,
those securities of the Purchaser listed on Schedule I attached hereto (the “Purchased Securities”), on the
terms and subject to the conditions set forth in this Agreement; and
WHEREAS, the transactions
contemplated by this Agreement (collectively, the “Transactions”) will be consummated pursuant to and in accordance
with the Bid Procedures Order and the Sale Order (each as defined below), pursuant to Sections 105 and 363 of Title 11 of the United
States Code, 11 U.S.C. §§ 101, et seq, as amended (the “Bankruptcy Code”).
NOW, THEREFORE,
in consideration of the foregoing and the mutual agreements, covenants, representations and warranties set forth herein, and in order
to prescribe the terms and conditions of such purchase and sale, intending to be legally bound, the Parties agree as follows:
| 1. | PURCHASE PRICE; DEPOSIT; TREATMENT of junior dip loan. |
Pursuant to Section 363 of the
Bankruptcy Code and on the terms and subject to the conditions of this Agreement, on the Closing Date (as defined below) and effective
as of the Effective Time (as defined below), the Seller shall sell to the Purchaser, and the Purchaser shall purchase from the Seller
the Purchased Securities listed on Schedule I attached hereto, free and clear of any Encumbrances or Liabilities. The aggregate
consideration for the Purchased Securities shall be (i) $100,000,000 which such amount is satisfied by the Oramed DIP Assumption (the
“DIP Amount”) plus (ii) a credit bid, on a dollar-for-dollar basis, pursuant to Section 363(k) of the Bankruptcy
Code, in respect of any and all amounts of principal and accrued but unpaid interest outstanding, and any other obligations of Sorrento
or Scintilla, in each case, under the Junior DIP Facility as of the Closing Date (the “Credit Bid Amount”) plus
(iii) $5,000,000 which the Purchaser paid to the Seller on September 13, 2023 as an advance payment of the Purchase Price (as defined
below) (the “Advance Payment”) plus (iv) $5,000,000 which the Purchaser shall pay to the Seller on the Closing
Date (the “Closing Payment”) plus (v) the assumption and assignment of all of the obligations of the Seller
to Paul Hastings LLP for legal fees and expenses reflected in Paul Hastings LLP’s proof of claim #238 filed with the Bankruptcy
Court in the amount of $12,249,244.09 (the “Legal Fee Assumption” and, together with the DIP Amount, the Credit Bid
Amount, the Advance Payment and the Closing Payment, the “Purchase Price”). Notwithstanding anything to the contrary
in this Agreement, the amount of Purchased Securities and Purchase Price per share shall be appropriately adjusted in the event of any
stock split, dividend, stock combination, reclassification or similar transaction occurring prior to the Closing Date. For the avoidance
of doubt, Purchaser will not assume any Liabilities, accounts payable, notes payable, expenses or other obligations of Seller or its Affiliates.
(a)
The sale and purchase of the Purchased Securities shall be effected by the Seller delivering to SCLX Stock Acquisition on the Closing
Date duly executed certificates or other instruments evidencing the Purchased Securities with instruments of transfer reasonably satisfactory
to the Purchaser (duly endorsed or otherwise in such form sufficient for transfer), against delivery by the Purchaser to the Seller of
the Purchase Price. The Purchase Price shall be paid by Purchaser to the Seller on or prior to the Closing Date in accordance with Section
1, with the Closing Payment being paid by wire transfer of immediately available funds in U.S. dollars to an account designated by
the Seller to the Purchaser in writing no later than two Business Days prior to the Closing Date.
(b)
The Purchaser will notify its transfer agent of the proposed Closing Date, and the Seller will deliver to the Purchaser or such
transfer agent documentation reasonably requested by the Purchaser or such transfer agent to effect the book-entry transfer of the Purchased
Securities by the Seller to the Purchaser. The Purchaser and/or its transfer agent will transfer the Purchased Securities to the Purchaser
in a restricted book-entry position on the books of the transfer agent and register the Purchaser as the registered owner of the Purchased
Securities as of the Effective Time. The Seller will cooperate with the Purchaser and will use reasonable best efforts to transfer the
Purchased Securities in the manner preferred by the Purchaser.
(c)
The closing of such sale and purchase of the Purchased Securities (the “Closing”) shall take place immediately
following the execution of this Agreement, remotely by conference call and electronic exchange of documentation, at 10:00 a.m. New York
time, or by such other means or at such other date and time as the Parties shall mutually agree (the date of the Closing, the “Closing
Date” and the time of the Closing, the “Effective Time”).
| 3. | REPRESENTATIONS AND WARRANTIES OF THE SELLER. |
The Seller represents and
warrants to the Purchaser, subject to such exceptions as are disclosed in the disclosure schedule (the “Seller Disclosure Schedule”)
delivered by the Seller to Purchaser concurrently with the execution and delivery of this Agreement as follows:
(a)
Organization. The Seller is a corporation duly organized, validly existing and in good standing under the laws of the State
of Delaware.
(b)
Authority. The Seller has authorized the execution, delivery and performance of this Agreement and each of the transactions
contemplated hereby, and, upon entry and effectiveness of the Sale Order (as defined below), no other action will be necessary to authorize
such execution, delivery and performance. Subject to and assuming the entry and effectiveness of the Sale Order, this Agreement constitutes
a legal, valid and binding obligation of the Seller, enforceable against the Seller in accordance with its terms.
(c)
No Violation; Consents.
(i)
No consent, approval, authorization or order (each a “Consent”) of any federal, municipal, state, local or foreign
governmental, administrative, taxing or regulatory authority, department, agency, commission or body (including any court, arbitrator,
or similar tribunal) (each a “Governmental Authority”) having jurisdiction over the Seller is required for the execution,
delivery or performance by the Seller of its obligations hereunder, including without limitation the sale of the Purchased Securities,
except for (A) the entry of the Sale Order by the Bankruptcy Court (as defined below) and (B) such consents, approvals, authorizations
or orders as have already been obtained or granted.
(ii)
Except to the extent excused by or unenforceable as a result of the Bankruptcy Case (as defined below) and except for the entry
and effectiveness of the Sale Order, neither the sale of the Purchased Securities nor the performance of the Seller’s obligations
hereunder will violate, conflict with, result in a breach or termination of, extinguish any material rights, or constitute a default (or
an event that, with the giving of notice or the lapse of time, or both, would constitute a default) under (i) the certificate of incorporation,
bylaws or other Organizational Documents of the Seller (ii) any decree, judgment, order, law, treaty, rule, regulation or determination
of any Governmental Authority (“Laws”) having jurisdiction over the Seller or any of its respective assets or properties,
or (iii) the terms of any Material Contract, except in each case as would not reasonably be expected to have the effect of preventing,
materially delaying, making illegal or otherwise materially interfering with any of the transactions contemplated by this Agreement.
(d)
Capitalization. Other than that certain Stockholder Agreement, dated as of September 12, 2022, between the Purchaser and
the Seller and that certain Amended and Restated Registration Rights Agreement, dated as of November 10, 2022, among the Purchaser, the
Seller and the other parties thereto, there are no stockholder agreements, voting trusts or other agreements or understandings to which
the Seller is a party or by which it is bound relating to the voting or registration of any shares of capital stock of the Purchaser or
any of its Subsidiaries or preemptive rights with respect thereto.
(e)
Title to Purchased Securities. The Seller has good, valid and marketable title to the Purchased Securities, and, subject
to receipt of the Sale Order, good, valid and marketable title will be transferred to the Purchaser free and clear of any charge, lien
(statutory or otherwise), mortgage, lease, hypothecation, encumbrance, pledge, security interest, option, right of use, first offer or
first refusal, voting trusts, proxies, easement, servitude, restrictive covenant, encroachment or similar restriction, other than those
imposed by the Securities Act (each, an “Encumbrance”, and collectively, “Encumbrances”). The Purchased
Securities, constitute all of the shares of capital stock of the Purchaser (or options, warrants or rights to purchase shares of capital
stock of the Purchaser or securities convertible into or exchangeable for shares of capital stock of the Purchaser) owned by the Seller
(other than those certain 1,917,210 shares of common stock of the Purchaser that the Seller is currently holding in abeyance on behalf
of certain warrantholders of the Seller).
(f)
Legal Proceedings and Orders. Other than in connection with the Bankruptcy Case, to the Knowledge of Seller, there is no
action, suit, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding or any informal
proceeding) or investigation pending or being heard by or before, or otherwise involving, any Governmental Authority or any arbitrator
or arbitration panel (each a “Proceeding”) and no Person has threatened in writing to commence any Proceeding, in each
case, that would reasonably be expected to have the effect of preventing, materially delaying, making illegal or otherwise materially
interfering with any of the Transactions contemplated by this Agreement. To the Knowledge of Seller, and except as described in Section
3(f) of the Seller Disclosure Schedule, there is no governmental order, writ, injunction, judgment or decree to which the Purchased
Securities are subject.
(g)
SEC Matters. The sale of the Purchased Securities by the Seller is not part of a plan or scheme to evade the registration
requirements of the Securities Act. Neither the Seller nor any Person (as defined below) acting on behalf of the Seller has offered or
sold any of the Purchased Securities by any form of general solicitation or general advertising.
(h)
Brokers. Except as set forth in Section 3(h) of the Seller Disclosure Schedule, no Person is entitled to any brokerage,
financial advisory, finder’s or similar fee or commission payable by the Seller or any of its Affiliates in connection with the
Transactions contemplated by this Agreement.
(i)
No Reliance. In making its decision to sell the Purchased Securities, the Seller represents that it has not relied on, and
expressly disclaims reliance on, any statements or other information provided by any Person (including, without limitation, the Purchaser)
(other than the representations and warranties of the Purchaser set forth in Section 4).
(j)
Disclaimer of Additional Warranties. Except as expressly set forth in this Section 3, neither the Seller nor any
of its directors, members, officers, employees or representatives nor any other Person makes or has made any representation or warranty,
express or implied, at law or in equity, in respect of the Seller, the Purchased Securities or the transactions contemplated by this Agreement,
and the Seller disclaims any other representations or warranties, whether made by the Seller or any other Person, in each case notwithstanding
the delivery or disclosure to the Purchaser or any other Person of any documentation or other information with respect to the foregoing.
| 4. | REPRESENTATIONS AND WARRANTIES OF THE PURCHASER |
The Purchaser represents and
warrants to the Seller as follows:
(a)
Organization. The Purchaser is a corporation duly organized, validly existing and in good standing under the laws of the
State of Delaware.
(b)
Authority. The Purchaser has authorized the execution, delivery and performance of this Agreement and each of the transactions
contemplated hereby, and, upon entry and effectiveness of the Sale Order, no other action will be necessary to authorize such execution,
delivery and performance. Subject to and assuming the entry and effectiveness of the Sale Order, this Agreement shall constitute a legal,
valid and binding obligation of the Purchaser, enforceable against the Purchaser in accordance with its terms.
(c)
No Violation; Consents.
(i)
No Consent of any Governmental Authority having jurisdiction over the Purchaser is required for the execution, delivery or performance
by the Purchaser of its obligations hereunder, including without limitation the purchase of the Purchased Securities, except for the entry
of the Sale Order by the Bankruptcy Court.
(ii)
Except to the extent excused by or unenforceable as a result of the filing of the Bankruptcy Case and except for the entry and
effectiveness of the Sale Order, neither the acquisition of the Purchased Securities nor the performance of the Purchaser’s obligations
hereunder will violate, conflict with, result in a breach of or termination of, extinguish any rights, or constitute a default (or an
event that, with the giving of notice or the lapse of time, or both, would constitute a default) under (i) the certificate of incorporation,
bylaws or other Organizational Documents of the Purchaser, (ii) any Laws of any Governmental Authority having jurisdiction over the Purchaser
or any of its assets or properties or (iii) the terms of any material agreement to which the Purchaser is a party or to which any of the
Purchaser’s properties is subject, except in each case as would not reasonably be expected to have the effect of preventing, materially
delaying, making illegal or otherwise materially interfering with any of the transactions contemplated by this Agreement.
(d)
Sufficient Funds. The Purchaser has sufficient cash in immediately available funds to pay the Closing Payment and all of
the fees, costs and expenses incurred in connection with the transactions contemplated hereby by the Purchaser (without giving effect
to any unfunded financing, regardless of whether any such financing is committed).
(e)
Solvency. Assuming the accuracy of the representations and warranties of Seller set forth in Section 3 (disregarding any
materiality, knowledge or similar qualifications or exceptions contained therein), immediately after giving effect to the transactions
contemplated hereby (including, without limitation, the Oramed DIP Assumption), the Purchaser shall (i) be able to pay its debts as they
become due; (ii) own property which has a fair saleable value greater than the amounts required to pay its debts (including a reasonable
estimate of the amount of all contingent liabilities); and (iii) have adequate capital to carry on its business. No transfer of property
is being made and no obligation is being incurred in connection with the transactions contemplated hereby with the intent to hinder, delay
or defraud either present or future creditors of the Purchaser.
(f)
Acknowledgement. The Purchaser acknowledges and understands that the Purchase Price represents a mutually agreed upon price
for the Purchased Securities determined by the Purchaser and the Seller and does not necessarily represent the fair market value of the
Purchased Securities as of the date hereof, as of the Closing or in the future.
(g)
Tax Classification. SCLX Stock Acquisition is a direct, wholly-owned subsidiary of the Purchaser that, for U.S. federal
and applicable state and local income Tax purposes, is treated as a disregarded entity.
| 5. | COVENANTS OF THE PARTIES. |
(a)
[Reserved].
(b)
[Reserved].
(c)
Further Assurances. At all times from and after the Closing, each of the Parties shall use its reasonable best efforts to
take, or cause to be taken, all actions, and to do, or cause to be done, all things reasonably necessary, proper or advisable consistent
with applicable Laws or reasonably requested to consummate and make effective in the most expeditious manner practicable the Transactions
contemplated by this Agreement and the other Transaction Documents.
(d)
No Encumbrances. At the Effective Time, Seller shall sell and transfer the Purchased Securities to the Purchaser, free and
clear of any Encumbrances or Liabilities.
(e)
[Reserved].
(f)
[Reserved].
(g)
Tax Matters.
(i)
Cooperation on Tax Matters. The Parties shall use commercially reasonable efforts to cooperate, as and to the extent reasonably
requested by any other party, and at such requesting party’s expense, in connection with the filing of Tax Returns and any audit,
litigation or other proceeding with respect to Taxes relating to Tax periods (or portions thereof) ending on or before the Closing Date.
Such cooperation shall include the retention and (upon a reasonable request) the provision of records and information that are reasonably
relevant to any filing of Tax Returns including the transactions contemplated hereby and any such audit, litigation or other proceeding
and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided
hereunder. The Seller agrees (A) to retain all books and records in its possession with respect to Taxes of the Purchaser and its Subsidiaries
relating to any taxable period beginning before the Closing Date for up to seven (7) years, and (B) to give the Purchaser reasonable written
notice prior to transferring, destroying or discarding any such books and records and shall allow the Purchaser to take possession of
such books and records. For the avoidance of doubt, the Seller shall not be required to share tax information or books and records with
the Purchaser with respect to the Seller or the Seller’s consolidated, combined, unitary or affiliated tax group, except to the
extent there is an audit, litigation or other proceeding with respect to the Seller’s Income Taxes with respect to a taxable period
for which the Purchaser was a member of the Seller’s consolidated, combined, unitary or affiliated tax group and the Purchaser is
reasonably expected to have liability for all or a portion of any resulting Tax liability.
(ii)
The Parties agree, upon reasonable request and at such requesting party’s expense, to use their commercially reasonable efforts
to obtain any certificate or other document from any governmental authority or any other Person as may be necessary to mitigate, reduce
or eliminate any Tax that could be imposed with respect to the transactions contemplated hereby.
(iii)
Transfer Taxes. All transfer, documentary, sales, use, stamp, registration and other such Taxes, and all conveyance fees,
recording charges and other fees and charges (including any penalties and interest) incurred in connection with consummation of the transactions
contemplated by this Agreement and actually due and owing shall be borne and paid by the Purchaser when due, and Purchaser will file all
necessary Tax Returns and other documentation with respect to all such Taxes, fees and charges, and, if required by applicable law, each
Party will, and will cause its Affiliates to, join in the execution of any such Tax Returns and other documentation.
(iv)
Tax Election. The Purchaser agrees not to file any entity classification election pursuant to Treasury Regulations Section
301.7701-3 to classify SCLX Stock Acquisition as a corporation for U.S. federal income tax purposes which election shall be effective
on or before the day after the Closing Date.
(h)
Submission for Bankruptcy Court Approval.
(i)
The Seller has given notice under the Bankruptcy Code of the request for the relief in the Sale Order to all Persons entitled to
such notice, including all Persons that have asserted Encumbrances in the Purchased Securities, and shall give such additional notice
as the Bankruptcy Court shall direct or as the Purchaser may reasonably request, and provide appropriate opportunity for hearing, to all
parties entitled thereto, of all motions, orders, hearings, or other proceedings in the Bankruptcy Court relating to this Agreement or
the transactions contemplated hereby. The Seller shall be responsible for making all appropriate filings relating thereto with the Bankruptcy
Court, which filings shall be submitted, to the extent practicable, to the Purchaser prior to their filing with the Bankruptcy Court for
the Purchaser’s prior review and comments (which comments the Seller shall consider in good faith).
(ii)
The Parties shall consult with one another regarding pleadings which any of them intends to file with the Bankruptcy Court in connection
with, or which might reasonably affect, the Sale Order. The Seller shall promptly provide the Purchaser and its counsel with copies of
all notices, filings and orders of the Bankruptcy Court that the Seller has in its possession (or receives) pertaining to the Sale Order
or any other order related to any of the transactions contemplated by this Agreement, but only to the extent such papers are not publicly
available on the Bankruptcy Court’s docket or otherwise made available to the Purchaser and its counsel.
(iii)
The Parties shall comply in all material respects with all of their obligations under the Sale Order.
(iv)
If the Bid Procedures Order, the Sale Order or any other orders of the Bankruptcy Court relating to this Agreement or the transactions
contemplated hereby shall be appealed by any Person (or if any petition for certiorari or motion for reconsideration, amendment, clarification,
modification, vacation, stay, rehearing or reargument shall be filed with respect to the Bid Procedures Order, the Sale Order or other
such order), subject to rights otherwise arising from this Agreement, the Parties shall use their commercially reasonable efforts to prosecute
such appeal, petition or motion and obtain an expedited resolution of any such appeal, petition or motion.
(i)
[Reserved].
(j)
[Reserved].
(k)
Receipt of Property Relating to Purchased Securities. If, following the Closing, the Seller (or its respective Affiliates
or Representatives) shall receive any money, check, note, draft, instrument, payment or other property as proceeds of the Purchased Securities
or any part thereof, and to the extent arising from any fact, event or circumstance after the Closing, each such Person shall receive
all such items in trust for, and as the sole and exclusive property of, Purchaser and, upon receipt thereof, shall notify Purchaser in
writing of such receipt and shall remit the same (or cause the same to be remitted) to Purchaser in the manner reasonably specified by
Purchaser.
(l)
Post-Closing Operation of the Seller; Name Changes. After the Closing Date, none of the Seller and any of its Affiliates
shall use the name or mark “Scilex” or any derivatives thereof for commercial purposes. After the Closing, the Seller and
its Affiliates shall promptly file with the applicable Governmental Authorities all documents reasonably necessary to delete from their
names the words “Scilex” or any derivatives thereof and shall do or cause to be done all other acts, including the payment
of any fees required in connection therewith, to cause such documents to become effective as promptly as reasonably practicable. For clarity,
nothing in this Section 5(l) shall restrict the Seller or any of its Affiliates from using or referencing the name or mark “Scilex”
or any derivatives thereof (i) in a non-trademark manner to describe or provide information regarding the history of the Purchased Securities,
or (ii) as required by applicable Law, including in any filing with the SEC, documents filed with the Bankruptcy Court or financial
statements.
(m)
Transition Services.
(i)
Subject to the terms and conditions of this Section 5(m), the Seller will, for a period of up to 120 days following the
Closing, provide to the Purchaser a continuation of those services that the Seller has provided to the Purchaser at any time since December
1, 2022 (the “Transition Services”), on the same terms and conditions (including cost) as previously provided between
the Seller and the Purchaser; provided however, that:
(1)
the Seller shall have the right to make such changes to the Transition Services as are necessary in order to comply with applicable
Laws or Permits to which the Seller or its Affiliates is a party or subject;
(2)
the Seller shall not be responsible for any act or omission of a third party provider and the Purchaser’s sole and exclusive
remedy in respect of such acts or omissions shall be the Seller’s use of commercially reasonable efforts to cause such third party
to perform or re-perform the Transition Services and/or to seek available remedies under the applicable Contract with such third party
provider;
(3)
nothing contained in this Section 5(m) shall require the Seller to provide any services that would constitute the provision
of any legal or tax advice or regulated activity, or that would create deficiencies in the Seller’s controls over financial information
or adversely affect the maintenance of the Seller’s financial books and records; and
(4)
in no event shall the Seller be obligated to hire replacements for employees providing Transition Services that resign, retire
or are terminated; provided, however, that in such case, the Seller will use commercially reasonable efforts to provide
the applicable Transition Services.
(ii)
The aggregate liability of Seller in connection with the performance of the Transition Services shall not exceed the total fees
actually paid or payable by the Purchaser to Seller in respect of the Transition Services. Notwithstanding anything else in this Agreement
to the contrary, and solely with respect to the Transition Services, Seller shall not be liable for any special, indirect, punitive or
consequential damages which substantially arise out of, relate to or are a consequence of the performance of the Transition Services,
except in the event of the Seller’s gross negligence, willful misconduct or fraud. Seller acknowledges and agrees that irreparable
damage would occur in the event that any of the provisions of this Section 5(m) were not performed by them in accordance with the
terms hereof or were otherwise breached and that the Purchaser shall be entitled to an injunction or injunctions to prevent breaches of
the provisions of this Section 5(l) and to enforce specifically the provisions of this Section 5(m) (without any requirement
to post any bond or other security in connection with seeking such relief), in addition to any other remedy at law or equity, and Seller
further agrees not to raise any objections to the availability of the equitable remedy of specific performance to prevent or restrain
breaches of this Section 5(m) by the Seller, and to specifically enforce the terms and provisions of this Section 5(m).
(iii)
The Purchaser may terminate all or any portion of the Transition Services before the expiration of such 120-day period, by delivering
written notice of such termination to the Seller.
(iv)
Nothing in this Section 5(m) shall grant or transfer any rights, title or interests in any Intellectual Property invented
or created before, on or after the Closing by or on behalf of the Seller or its Affiliates or otherwise controlled by or licensed to the
Seller or its Affiliates.
(v)
The Purchaser shall pay any applicable costs invoiced to the Purchaser by the Seller within 30 days after receipt thereof by wire
transfer of immediately available funds to an account designated by the Seller in writing.
(n)
Acknowledgement. Each of the Parties acknowledges and represents that: (i) sufficient consideration has been given by each
Party to the other Parties as it relates hereto and the covenants, obligations and agreements hereunder were taken into account in determining
the amount of such consideration; (ii) each of the Parties has consulted with independent legal counsel regarding its rights and obligations
under this Section 5; (iii) each of the Parties fully understands the terms and conditions contained herein; (iv) the restrictions
and agreements in this Section 5 are reasonable in all respects and, as applicable, necessary for the protection of the Business
and that, without such protection, the customer and client relationships and competitive advantage relating to the Business would be materially
adversely affected; and (v) the agreements in this Section 5 are an essential inducement to each Party to enter into this
Agreement and they are in addition to, rather than in lieu of, any similar or related covenants to which either Party is party or by which
it is bound.
This Agreement may only be
enforced against, and any claim or cause of action pursuant to the terms of this Agreement (including any representation or warranty made
in, in connection with, or as an inducement to this Agreement) may only be brought against, the entities that are expressly named as Parties
hereto and then only with respect to the specific obligations set forth herein with respect to such Party. Except to the extent a named
Party to this Agreement (and then only to the extent of the specific obligations undertaken by such named Party in this Agreement and
not otherwise), no past, present or future manager, director, officer, employee, incorporator, member, partner, equityholder, Affiliate,
agent, attorney, advisor or representative or Affiliate of any named Party to this Agreement shall have any liability (whether in contract,
tort, equity or otherwise) for any one or more of the representations, warranties, covenants, agreements or other obligations or liabilities
of any one or more of the named Parties to this Agreement.
| 9. | SURVIVAL OF REPRESENTATIONS AND WARRANTIES. |
(a)
None of the representations and warranties of the Parties in this Agreement shall survive the Closing, and no Party hereto shall,
or shall be entitled to, make any claim or initiate any action against any other Party with respect to any such representation or warranty
from or after the Closing.
(b)
None of the covenants or agreements of the Parties in this Agreement shall survive the Closing, and no Party hereto shall, or shall
be entitled to, make any claim or initiate any action against any other Party with respect to any such covenant or agreement from or after
the Closing, other than (i) the covenants and agreements of the Parties contained in this Section 9 and in Sections 1,
2 and 10, and (ii) those other covenants and agreements contained herein that by their terms apply, or that are to
be performed in whole or in part, after the Closing, which shall survive the consummation of the transaction contemplated by this Agreement
until fully performed.
| 10. | DEFINITIONS; MISCELLANEOUS. |
(a)
Terms Defined. As used in this Agreement, the following terms have the respective meanings set forth below:
“Affiliate”
means any Person that directly or indirectly controls, is controlled by, or is under control with, such Person. The term “control”
(including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly,
of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities,
by contract or otherwise.
“Bankruptcy Case”
means the Seller’s and Scintilla’s voluntary proceedings under Chapter 11 of the Bankruptcy Code in the Bankruptcy Court,
which are being jointly administered under the caption In re Sorrento Therapeutics,
Inc., et al, Case No. 23-90085 (Bankr. S.D. Tex.).
“Bankruptcy Court”
means the United States Bankruptcy Court for the Southern District of Texas or such other court having competent jurisdiction over the
Bankruptcy Case.
“Benefit Plan”
means each “employee benefit plan” (as defined in Section 3(3) of ERISA or any similar plan subject to Laws of a jurisdiction
outside of the United States, whether or not subject to ERISA), and any other plan, policy, program or agreement providing compensation
or other benefits to any current or former director, officer, employee or other individual service provider of the Purchaser or any of
its Subsidiaries (whether qualified or nonqualified or funded or unfunded or written or unwritten), in each case, (i) which is maintained,
sponsored by, contributed to or required to be contributed to by the Purchaser or any of its Subsidiaries, or (ii) under which the Purchaser
or any of its Subsidiaries has or would reasonably be expected to have any obligation or Liability.
“Bid Procedures Order”
means the Order (I) Approving Bid Procedures, (II) Approving Assumption and Assignment Procedures, and (III) Granting Related Relief
[ECF No. 447] entered by the Bankruptcy Court on April 14, 2023.
“Business”
means the business and operations of the Purchaser and its Subsidiaries, taken as a whole.
“Business Day”
shall mean any day that is not a Saturday, Sunday or other day on which banks are permitted or required to be closed in New York City.
“Code” means
the Internal Revenue Code of 1986, as amended.
“Common Stock”
means the shares of Common Stock of the Company set forth on Schedule I.
“Contract”
means any contract, sub-contract, agreement, lease or sub-lease, license or sub-license, occupancy agreement, purchase order, supply agreement,
commitment, note, bond, franchise, guarantee, indemnity, indenture, instrument, lease, license or other legally binding arrangement, understanding,
or obligation, whether written or oral (including all amendments, side letters, supplements and modifications of any of the foregoing
and all rights and interests arising thereunder or in connection therewith, but excluding any Benefit Plan).
“ERISA” means
the Employee Retirement Income Security Act of 1974, as amended, and all Laws issued thereunder.
“Exchange Act”
means the Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Income Tax”
means any federal, state, local, or non-U.S. income tax measured by or imposed on net income, including any interest, penalty, or addition
thereto.
“Intellectual Property”
shall mean all rights, title and interest (whether statutory, common law or otherwise) in or relating to any intellectual property, including
all: (i) patents and patent applications, and all related national or international counterparts thereto, including any divisionals, continuations,
continuations-in-part, reissues, reexaminations, substitutions provisionals, renewals, extensions, patents of addition, supplementary
protection certificates, utility models, inventors’ certificates, or the like, and any foreign equivalents of any of the foregoing
(including certificates of invention and any applications therefor) and all rights to claim priority from any of the foregoing; (ii) trademarks,
trade dress, service marks, certification marks, logos, slogans, design rights, names, corporate names, trade names, brand names and other
similar designations of source or origin, together with the goodwill symbolized by any of the foregoing, and all applications, registrations,
renewals and extensions of any of the foregoing; (iii) copyrights and copyrightable subject matter, whether or not registered or published,
and all applications, registrations, reversions, extensions and renewals of any of the foregoing, and all moral rights, however denominated;
(iv) trade secrets, and all other confidential or proprietary information, ideas, technology, software, compositions, discoveries, improvements,
know-how, inventions, designs, processes, techniques, formulae, models, and methodologies, in each case, whether or not patentable or
copyrightable; (v) Internet domain names and social media accounts and addresses, and all registrations for any of the foregoing; and
(vi) rights and remedies with respect to any past, present, or future infringement, misappropriation, or other violation of any of the
foregoing in clauses (i) through (v), in each case (i) through (vi), anywhere in the world.
“Knowledge”
means, as to a particular matter, the actual knowledge of (i) with respect to Purchaser, its chief executive officer or its chief
financial officer, and (ii) with respect to the Seller, Mohsin Meghji.
“Liability”
means any liability (including any unknown, undisclosed, unmatured, unaccrued, unasserted, contingent, direct, indirect, conditional,
implied, vicarious, derivative, joint, several or secondary liability), debt, obligation, deficiency, interest, tax, penalty, fine, penalty,
claim, demand, judgment, cause of action or other loss (including loss of benefit or relief), cost or expense of any kind or nature whatsoever,
whether asserted or unasserted, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, and whether due or to become
due and regardless of when asserted.
“Material Contract”
means any contract to which the Seller is a party that was filed by the Seller pursuant to Exhibit 10, as specified in Regulation S-K
Item 601(b)(10), with its annual report on Form 10-K for the fiscal year ended December 31, 2022, or any subsequent current report on
Form 8-K or any quarterly report on Form 10-Q.
“Oramed DIP Assumption”
means the assignment to Purchaser by Sorrento and Scintilla of their respective rights and obligations under that certain Senior Secured,
Super-Priority Debtor-in-Possession Loan and Security Agreement, by and among Oramed Pharmaceuticals, Inc., a Delaware corporation (“Oramed”),
on the one hand, and Sorrento and Scintilla, on the other, dated as of August 8, 2023 (the “Senior DIP”), the assumption
by the Purchaser of such rights, title and interests, duties, liabilities and obligations and the irrevocable and unconditional release
by the Purchaser and Oramed of Sorrento and Scintilla from any and all claims, liabilities and obligations under the Senior DIP, in each
case, pursuant to documentation entered into between Oramed, Sorrento and the Purchaser on the date hereof.
“Organizational Documents”
means the articles of incorporation, certificate of incorporation, charter, by-laws, articles of formation, articles of organization,
certificate of formation, regulations, operating agreement, certificate of limited partnership, limited liability company agreement or
partnership agreement, stockholders agreement and all other similar documents, instruments or certificates executed, adopted or filed
in connection with the creation, formation, organization or governance of a Person, including any amendments thereof and any supplements
thereto.
“Permit”
shall mean franchises, grants, authorizations, registrations, licenses, permits, easements, variances, exceptions, certificates, and approvals
of any Governmental Authority.
“Person”
means an individual, partnership, joint-stock company, corporation, limited liability company, trust or unincorporated organization, and
a government or agency or political subdivision thereof.
“Preferred Stock”
means the shares of Series A Preferred Stock of the Company set forth on Schedule I.
“Representative”
of any Person shall mean such Person’s directors, managers, officers, employees, agents, attorneys, consultants, advisors or other
representatives.
“Sale Order”
means the Order (I) Approving Sale of Scilex Stock to Scilex Holding Company Free and Clear of All Liens, Claims, Interests, and Encumbrances,
(II) Conditionally Vacating the Oramed Sale Order, and (III) Granting Related Relief [ECF No. 1316].
“SCLX Stock Acquisition”
means SCLX Stock Acquisition JV LLC, a Texas limited liability company that is a wholly-owned subsidiary of the Purchaser.
“Securities Act”
means the Securities Act of 1933, as amended.
“Subsidiary”
of any Person means any other Person, of which such first Person (either alone or with any other Subsidiary) owns or controls, directly
or indirectly, stock, other securities or other equity interests (i) having the ordinary voting power to elect a majority of the board
of directors or other governing body of such Person, or (ii) representing at least fifty percent (50%) of the outstanding stock, other
securities or other equity interests of such Person.
“Tax” means
any U.S. federal, state, local or non-U.S. tax (including any income tax, franchise tax, service tax, capital gains tax, gross receipts
tax, value-added tax, surtax, excise tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax, property tax, business tax, withholding
tax or payroll tax), levy, assessment, tariff, duty (including any customs duty), deficiency or fee (including any fine, addition, penalty
or interest), imposed by any Governmental Authority (to the extent the foregoing are taxes or in the nature of a tax).
“Tax Return”
means any return, declaration, report, claim for refund, or information return or statement relating to Taxes, including any schedule
or attachment thereto, and including any amendment thereof, required to be filed by the Purchaser or any of its Subsidiaries to a tax
authority.
“Transaction Documents”
means collectively, this Agreement, the schedules and exhibits attached hereto (including the Seller Disclosure Schedule), and any and
all agreements, certificates, instruments and other documents of the Parties required thereby or executed in connection therewith.
“Warrants”
means the Warrants of the Company set forth on Schedule I.
(b)
Public Announcements; Reporting Obligations.
(i)
Each of the Parties may make any filings or public announcement it reasonably deems necessary in order to comply with the requirements
of any applicable Law, including without limitation the filing by the Parties of any Form 8-K, Schedule 13G or Schedule 13G/A, Schedule
13D or Schedule 13D/A, Form 3, Form 4 or other appropriate filings with the SEC. Except as a Party reasonably deems necessary in order
to comply with the requirements of any applicable Law, no Party may issue any press release or make any other public announcement relating
to the subject matter of this Agreement or the Transactions contemplated hereby without the prior written consent of the other Party,
which shall not be unreasonably withheld, conditioned or delayed.
(ii)
The Purchaser acknowledges and agrees that it shall be solely responsible for the filing, as and if applicable, of (1) any Forms
3, 4 and 5 in accordance with Section 16(a) of the Exchange Act and the rules promulgated thereunder, and (2) any Schedule 13D or 13G,
as applicable, under the Exchange Act and the rules promulgated thereunder, in each case, in respect of its ownership of a registered
class of securities of the Purchaser.
(c)
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable
to contracts made and to be performed entirely within such State. All actions and proceedings arising out of or relating to this Agreement
and the transactions contemplated hereby shall be heard and determined exclusively in the United States Bankruptcy Court for the Southern
District of Texas, and the Parties hereby irrevocably submit to the exclusive jurisdiction of such court in any such action or proceeding
and irrevocably waive the defense of an inconvenient forum to the maintenance of any such action or proceeding; provided, however,
that, if the Bankruptcy Case is closed, any action, claim, suit or proceeding arising out of, based upon, or relating to this Agreement
or the transactions contemplated herby shall be heard and determined exclusively in any state or federal court located in New York County,
New York. Each Party agrees that a final, non-appealable judgment in any such action or proceeding shall be conclusive and may be enforced
in other jurisdictions by suit on the judgment or in any other manner provided by law. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY
CONTROVERSY THAT MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY
AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF
OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
(d)
Section Headings. The headings of the sections and subsections of this Agreement are inserted for convenience only and shall
not be deemed to constitute a part thereof.
(e)
Notices.
(i)
All communications under this Agreement shall be in writing and shall be delivered by hand, mailed by overnight courier or by registered
or certified mail, postage prepaid or by e-mail:
(1)
if to the Purchaser, at Scilex Holding Company, Attention: Stephen Ma and Henry Ji (e-mail: SMa@scilexholding.com; HJi@sorrentotherapeutics.com),
or at such other address or e-mail address as the Purchaser may have furnished the Seller in writing, with a copy (which shall not constitute
notice) to: Paul Hastings LLP, 600 Travis Street, Fifty-Eighth Floor, Houston, TX 77002, Attention: Luis F. Gomar, James Grogan, Justin
Rawlins (e-mail: luisgomar@paulhastings.com; jamesgrogan@paulhastings.com; justinrawlins@paulhastings.com).
(2)
if to the Seller, to 4955 Directors Place, San Diego, California 92121, Attention: Mohsin Y. Meghji, Chief Restructuring Officer
(e-mail: mmeghji@m3-partners.com), or at such other address or e-mail address as it may have furnished in writing to the Purchaser, with
a copy (which shall not constitute notice) to: Latham & Watkins LLP, 10250 Constellation Blvd. Suite 1100, Los Angeles, CA 90067,
Attention: Andrew Clark; Caroline Reckler; Steven Feldman (e-mail: andrew.clark@lw.com; caroline.reckler@lw.com; steve.feldman@lw.com).
(ii)
Any notice so addressed shall be deemed to be given: if delivered by hand, on the date of such delivery; if mailed by courier,
on the first Business Day following the date of such mailing; if mailed by registered or certified mail, on the third Business Day after
the date of such mailing; and if delivered by e-mail (with no error message received), on the date of such delivery.
(f)
Expenses and Taxes. Each Party shall bear its own expenses incurred in connection with this Agreement and the consummation
of the transactions contemplated hereby; provided, that the Purchaser shall bear any transfer taxes payable in connection with
the transfer of the Purchased Securities to the Purchaser.
(g)
Successors and Assigns. Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned
or delegated by the Purchaser or the Seller. This Agreement shall inure to the benefit of and be binding upon the successors and permitted
assigns of each of the parties, including the trustee in the Bankruptcy Case. Notwithstanding the foregoing or anything in this Agreement
to the contrary, the Purchaser may assign this Agreement and/or any of its rights, interests, or obligations hereunder (in whole or in
part) to an Affiliate of the Purchaser; provided, however, that such assignment shall not relieve the Purchaser of its obligations
hereunder. Purchaser may, without the consent of Seller, designate, effective as of the Closing, one or more Persons to acquire all, or
any portion of, the Purchased Securities or pay all or any portion of the Purchase Price; provided, however, that such designation
shall not relieve the Purchaser of its obligations hereunder. The above designation may be made by Purchaser by written notice to Seller
at least three (3) Business Days prior to the Closing Date. The Parties agree to modify any Closing deliverables in accordance with the
foregoing designation.
(h)
Remedies. The Parties agree that irreparable damage would occur if any provision of this Agreement were not performed in
accordance with its specific terms or was otherwise breached and that monetary damages may not be an adequate remedy for any breach or
threatened breach of any of the provisions of this Agreement. It is accordingly agreed that the Parties shall be entitled to an injunction
or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, and any such
injunction shall be in addition to any other remedy to which any Party is entitled, at law or in equity.
(i)
Entire Agreement; Amendment and Waiver. This Agreement constitutes the entire understanding of the Parties and supersedes
all prior understandings among such Parties, including the non-binding term sheet, dated September 11, 2023, among the Parties and Oramed.
This Agreement may be amended with (and only with) the written consent of the Seller and the Purchaser, and the observance of any term
of this Agreement may be waived in a writing signed by the party making such waiver.
(j)
Counterparts. This Agreement may be executed with counterpart signature pages or in one or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterpart signature pages or counterparts
of this Agreement may be executed and delivered by electronic means (including in .pdf format sent by electronic mail) and other electronic
signatures, and the receiving party may rely on the receipt of such document so executed and delivered by electronic means as if the original
had been received.
(k)
Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any
rule of Law or public policy, all other terms, conditions and provisions of this Agreement shall nevertheless remain in full force and
effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse
to any Party. Upon a determination that any term or other provision of this Agreement is invalid, illegal or incapable of being enforced,
the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible
in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest
extent possible.
(l)
Mutual Drafting. The Parties participated jointly in the negotiation and drafting of this Agreement and the language used
in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent. If an ambiguity or question
of intent or interpretation arises, then this Agreement will accordingly be construed as drafted jointly by the Parties, and no presumption
or burden of proof will arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.
(m)
Rules of Construction. The words “hereby,” “herein,” “hereof,” “hereunder”
and words of similar import refer to this Agreement as a whole (including any Exhibits and Schedules hereto) and not merely to the specific
section, paragraph or clause in which such word appears. All references herein to Articles, Sections, Exhibits and Schedules shall
be deemed references to Articles and Sections of, and Exhibits and Schedules to, this Agreement unless the context shall otherwise require.
The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without
limitation.” When calculating periods of time under this Agreement, reference to a “day” or “days” shall
refer to a calendar day unless otherwise expressly provided herein. The definitions given for terms in this Agreement shall apply
equally to both the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include
the corresponding masculine, feminine and neuter forms. Except as otherwise expressly provided herein, all references to “dollars”
or “$” shall be deemed references to the lawful money of the United States of America. The use of “or” is
not intended to be exclusive unless expressly indicated otherwise.
[Signature Pages Follow]
IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed and delivered as of the date first above written.
|
SELLER: |
|
|
|
SORRENTO THERAPEUTICS, INC. |
|
|
|
By: |
/s/ Mohsin Y. Meghji |
|
|
Name: Mohsin Y. Meghji |
|
|
Title: Chief Restructuring Officer |
|
PURCHASER: |
|
|
|
SCILEX HOLDING COMPANY, a Delaware corporation |
|
|
|
By: |
/s/ Jaisim Shah |
|
|
Name: Jaisim Shah |
|
|
Title: Chief Executive Officer and President |
Schedule I
Purchased Securities
Class or Type of Securities |
Number of Securities |
Common Stock |
60,068,585 |
Series A Preferred Stock |
29,057,097 |
Warrants |
Warrants exercisable for 1,386,617 shares of common stock of the Purchaser in respect of Public Warrants, and warrants exercisable for 3,104,000 shares of common stock of the Purchaser in respect of Private Placement Warrants (each as defined in the latest publicly filed Annual Report on Form 10-K of the Purchaser) |
Exhibit 2.2
MUTUAL TERMINATION AND RELEASE AGREEMENT
This Mutual Termination and
Release Agreement (this “Agreement”) is entered into as of September 21, 2023, by and between Sorrento Therapeutics,
Inc., a Delaware corporation, (“Sorrento”), and Oramed Pharmaceuticals, Inc., a Delaware corporation (“Oramed”,
and together with Sorrento, the “Parties”).
WHEREAS, on February
13, 2023, Sorrento, together with its wholly-owned subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under
Chapter 11 of the United States Bankruptcy in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy
Court”), which case has been administered under Case No. 23-90085 (DRJ) (the “Chapter 11 Case”);
WHEREAS, on August
7, 2023, Sorrento and Oramed entered into that certain Stock Purchase Agreement (as amended, the “Oramed Stock Purchase Agreement”);
WHEREAS, on September
11, 2023, in connection with the Chapter 11 Case and upon further negotiation between Sorrento, Scilex Holding Company, a Delaware corporation
(“Scilex”) and Oramed in connection with the proposed sale
by Sorrento and acquisition by Scilex of the Purchased Securities (as
defined in Scilex Stock Purchase Agreement (as defined below)), entered into that certain Non-Binding Term Sheet (the “Term
Sheet”), which includes as Exhibit A thereto that certain Term Sheet for Senior Secured Note and Warrants and Related Matters
(the “Senior Debt Term Sheet” and, together with the Short Form Term Sheet, the “Term Sheets”, and
the transactions contemplated thereby, collectively, the “Transactions”);
WHEREAS, the Bankruptcy
Court has, by order dated September 12, 2023 [Docket No. 1316] (the “Approval Order”), approved the Term Sheets, and
in connection therewith, (i) conditionally vacated the Oramed Stock Purchase Agreement and the order dated August 30, 2023 [Docket No.
1267], effective upon closing of the Transactions, and (ii) extended the restrictions on certain transfers of Scilex common stock set
forth in the Court’s Order Extending the Application of the Automatic Stay to Continue the Restricted Trading Period for Shares
of Scilex Stock Distributed to the Debtors’ Shareholders from September 1, 2023 to March 31, 2024;
WHEREAS, on September
[21], 2023, Sorrento and Scilex entered into that certain Stock Purchase Agreement (the “Scilex Stock Purchase Agreement”),
pursuant to which Sorrento agreed to sell and transfer to Scilex and Scilex agreed to purchase and acquire the Purchased Securities (as
defined therein); and
WHEREAS, in connection
with the closing of the Scilex Stock Purchase Agreement and in furtherance of the Transactions, Sorrento and Oramed desire to terminate
in all respects the Oramed Stock Purchase Agreement effective upon the closing of the Transactions, and to deliver mutual full, irrevocable
and unconditional releases of any and all claims and causes of action, including, without limitation, claims and causes of action relating
to or arising from or in connection with the Stock Purchase Agreement (and related documents) effective upon the closing of the Transactions.
NOW, THEREFORE, in
consideration of the mutual agreements contained herein, and good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Parties agree as follows:
Section 1.
Termination of the Oramed Stock Purchase Agreement. Pursuant to Section 7(a) of the Oramed Stock Purchase Agreement,
effective upon the closing of the Transactions, each of Sorrento and Oramed hereby consents to the termination of the Oramed Stock Purchase
Agreement, all of the other Transaction Documents (as defined in the Oramed Stock Purchase Agreement) and the transactions contemplated
by the Oramed Stock Purchase Agreement and such other Transactions Documents, and acknowledges and agrees that the Oramed Stock Purchase
Agreement and all of the other Transaction Documents are of no further force and effect and each of the Oramed Stock Purchase Agreement,
the other Transaction Documents and the transactions contemplated by the Oramed Stock Purchase Agreement and such other Transactions Documents
are hereby terminated in all respects.
Section 2.
Mutual Releases.
(a)
Effective upon the closing of the Transactions, each of Sorrento and Oramed, on behalf of itself and its predecessors, successors,
affiliates, heirs, administrators, executors, assigns and each of their respective officers, directors, partners, managers, members, financial
advisors, accountants, actuaries, shareholders, agents, attorneys, representatives, employees, direct and indirect parent entities, subsidiaries,
heirs, administrators, and executors and with respect to Sorrento, its estate and any trustee or other estate representative appointed
in the Chapter 11 Case or any successor case (collectively, and whether current or former, in each case in his, her, or its capacity as
such, the “Releasing Parties”), do hereby irrevocably and unconditionally release and discharge the other Party hereto
and such other Party’s predecessors, successors, affiliates, heirs, administrators, executors, assigns and each of their respective
officers, directors, partners, managers, members, financial advisors, accountants, actuaries, shareholders, agents, attorneys, representatives,
employees, direct and indirect parent entities, subsidiaries, heirs, administrators, and executors (collectively, and whether current
or former, in each case in his, her, or its capacity as such, the “Released Parties”), and each of them, of and from
any and all actions, suits, causes of action, contracts, debts, sums of money, controversies, claims, demands, liabilities, losses, judgments,
costs, attorney’s fees, damages and expenses, in each case of any kind whatsoever, whether in law, equity or otherwise, known or
unknown, actual or contingent, mature or unmatured, disputed or undisputed, accrued or not accrued, foreseen or unforeseen, then existing
or thereafter arising, in law, at equity or otherwise, whether individual, class, direct or derivative in nature, whether for tort, contract,
negligence, gross negligence, strict liability, contribution, subrogation, respondiat superior, breach of fiduciary duty, recharacterization,
subordination, violations of federal or state securities laws, rules or regulations, or otherwise, based, in whole or in part, on any
act, omission, transaction, event or other occurrence or circumstances (each, a “Claim” and collectively, “Claims”)
taking place on or before the date hereof which any of the Releasing Parties may now have or ever has had, prior to and including the
date hereof through, including, without limitation, any Claims relating to or arising in connection with the Oramed Stock Purchase Agreement
and the other Transaction Documents (as defined in the Oramed Stock Purchase Agreement), and the Breakup Fee and Expense Reimbursement
(each as defined in the Oramed Stock Purchase Agreement).
(b)
Each Party, on its own behalf and on behalf of its respective Releasing Parties, covenants not to directly or indirectly sue, participate
in any suit (unless lawfully compelled to do so by service with a subpoena or other legal process, demand, or order), or threaten to sue,
or otherwise assert any Claim or initiate any other action, arbitration, or proceeding, or in any other way assist others in any action,
arbitration, or proceeding (unless lawfully compelled to do so by service with a subpoena or other legal process, demand, or order), of
any kind (including, without limitation, lawsuits, arbitrations, administrative proceedings, proceedings before any government body, complaints,
or appeals), against any Released Party concerning, relating to, or arising from any of the Claims.
(c)
Each Party (on behalf of itself and its respective Releasing Parties) hereby: (i) acknowledges a familiarity with Section 1542
of the Civil Code of the State of California, which provides as set forth below this Section 2(c); (ii) recognizes that it may
have some claim, demand, or cause of action against the other Party or any of such other Party’s respective Released Parties of
which it (or its respective Releasing Parties) is unaware and unsuspecting, and which it is (or its respective Releasing Parties are)
giving up by signing this Agreement; and (iii) hereby expressly waives and relinquishes every right or benefit which he, she, or it has
under Section 1542 of the Civil Code of the State of California, and any similar statute under any other state or federal law, principle
of common law, or international or foreign law, to the fullest extent that such right or benefit may lawfully be waived, regardless
of whether such Party (or any its respective Releasing Parties) is aware of or suspects such Claims at the time such Party executes this
Agreement or whether it later discovers Claims that may be different than, or in addition to, those that such Party (or any of its respective
Releasing Parties) now knows or believes to exist regarding the subject matter of the release provided in Section 2(a).
“A GENERAL RELEASE
DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING
THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”
(d)
Notwithstanding anything in this Agreement to the contrary, (i) Sorrento’s obligations under that certain Senior Secured,
Super-Priority Debtor-in-Possession Loan and Security Agreement, by and among Oramed on the one hand, and Sorrento and Scilex on the other
hand, dated as of August 8, 2023 (the “Senior DIP”), any other definitive agreements entered into in connection therewith
and ancillary thereto and the Order (I) Authorizing the Debtors to (A) Obtain Replacement Senior Secured Superpriority Postpetition
Financing and (B) Use Cash Collateral, (II) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (III)
Modifying the Automatic Stay, (IV) Granting Stalking Horse Protections and (V) Granting Related Relief [Docket No. 1184] shall not
be released or discharged pursuant to this Agreement, and (ii) the terms of this Agreement shall not, and shall not be construed to, limit
(I) the terms and scope of the releases provided in Paragraphs 14, 17, and 20 of the Approval Order or (II) the terms of the that certain
Assignment, Assumption and Release Agreement entered into on the date hereof by Scilex, Oramed and Sorrento, including any release by
either of the Parties provided therein.
Section 3.
Miscellaneous.
(a)
Representations of the Parties. Each Party represents and warrants to the other that: (i) it has duly executed and delivered
this Agreement and it has all requisite corporate power and authority to execute this Agreement; (ii) its entrance into this Agreement
has been duly authorized by all necessary corporate action on the part of such Party; and (iii) this
Agreement constitutes the legal, valid, and binding obligation of such Party, enforceable against it in accordance with its terms.
(i)
Public Announcements. Each of the Parties may make any filings or public announcement it reasonably deems necessary in order
to comply with the requirements of any applicable Law, including, without limitation, the filing by any of the Parties of any Form 8-K,
Schedule 13G or Schedule 13G/A, Schedule 13D or Schedule 13D/A, Form 3, Form 4 or other appropriate filings with the SEC. Except as a
Party reasonably deems necessary to comply with the requirements of any applicable Law, no Party may issue any press release or make any
other public announcement relating to the subject matter of this Agreement or the Transactions contemplated hereby without the prior written
consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed.
(b)
Governing Law. This Agreement shall be governed by, and construed in accordance with, the law of the State of New York applicable
to contracts made and to be performed entirely within such State. All actions and proceedings arising out of or relating to this Agreement
shall be heard and determined exclusively in the United States Bankruptcy Court for the Southern District of Texas, and the Parties hereby
irrevocably submit to the exclusive jurisdiction of such court in any such action or proceeding and irrevocably waive the defense of an
inconvenient forum to the maintenance of any such action or proceeding; provided, however, that, if the Bankruptcy Case is closed,
any action, claim, suit or proceeding arising out of, based upon, or relating to this Agreement or the transactions contemplated herby
shall be heard and determined exclusively in any state or federal court located in New York County, New York. Each Party agrees that a
final, non-appealable judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit
on the judgment or in any other manner provided by law. Each Party hereto irrevocably waives any objection, including any objection to
the laying of venue or based on the grounds of forum non conveniens, which it may now or hereafter have to the bringing of any
action or proceeding in such jurisdiction in respect of this Agreement or any other document related hereto. EACH PARTY ACKNOWLEDGES
AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE
IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
(c)
Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any
rule of law, all other terms, conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as
the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Party.
Upon a determination that any term or other provision of this Agreement is invalid, illegal or incapable of being enforced, the Parties
shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible.
(d)
Mutual Drafting. The Parties participated jointly in the negotiation and drafting of this Agreement and the language used
in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent. If an ambiguity or question
of intent or interpretation arises, then this Agreement will accordingly be construed as drafted jointly by the Parties, and no presumption
or burden of proof will arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.
(e)
Headings. The headings of this Agreement are for purposes of reference only and shall not limit or otherwise affect the
meaning hereof.
(f)
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and assigns of each
of the Parties including, without limitation, with respect to Sorrento, any trustee or other estate representative appointed in the Chapter
11 Case or any successor case.
(g)
Counterparts. This Agreement may be executed with counterpart signature pages or in one or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterpart signature pages or counterparts
of this Agreement may be executed and delivered by electronic means (including in .pdf format sent by electronic mail) and other electronic
signatures, and the receiving party may rely on the receipt of such document so executed and delivered by electronic means as if the original
had been received.
[Signature Pages Follow]
IN WITNESS WHEREOF,
each of the undersigned has caused this Agreement to be duly executed and delivered as of the date first above written.
|
SORRENTO THERAPEUTICS, INC. |
|
|
|
By: |
/s/ Mohsin Y. Meghji |
|
|
Name: Mohsin Y. Meghji |
|
|
Title: Chief Restructuring Officer |
|
ORAMED PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Josh Hexter |
|
|
Name: Josh Hexter |
|
|
Title: Chief Business and Operating Officer |
Exhibit 10.1
ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT
THIS ASSIGNMENT, ASSUMPTION
AND RELEASE AGREEMENT (this “Agreement”) is executed on September 21, 2023 (the “Effective Date”),
by and among Scilex Holding Company (“Scilex”), Oramed Pharmaceuticals Inc. (“Oramed”),
Sorrento Therapeutics, Inc. (“Sorrento”), and Scintilla Pharmaceuticals, Inc. (together with Sorrento, the “Debtors”).
W I T N E S S E T H:
WHEREAS, on February
13, 2023, the Debtors commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy
Code”) in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”).
The Debtors’ Chapter 11 proceedings are jointly administered under the caption In re Sorrento Therapeutics, Inc., et al.,
Case Number 23-90085 (DRJ) (the “Chapter 11 Cases”);
WHEREAS, the Debtors
have been conducting a marketing process for the sale or disposition of all or any portion of the Debtors’ assets under section
363 of the Bankruptcy Code, including (x) the Debtors’ equity interests in its non-debtor subsidiaries, including, but not limited
to, Scilex and (y) the Debtors’ other assets;
WHEREAS, Oramed agreed,
and after a hearing before the Bankruptcy Court on August 7, 2023, the Bankruptcy Court approved, pursuant to that certain Senior Secured,
Super-Priority Debtor-In-Possession Loan and Security Agreement (the “DIP Loan Agreement”) entered into on August
9, 2023, to provide a non-amortizing super-priority senior secured debtor-in-possession term loan facility (the “Senior DIP
Facility”) in an aggregate principal amount of $100,000,000, which amount was subsequently drawn in full by the Debtors.
As of the Effective Date, the aggregate outstanding Obligations under the Senior DIP Facility is $101,875,000, comprised of $100,000,000
principal, $875,000 accrued and unpaid interest and $1,00,000 fees and expenses payable under the Senior DIP Facility (the “DIP
Facility Obligations”); capitalized terms used herein but otherwise defined shall have the meanings so defined in the DIP
Loan Agreement;
WHEREAS, on September
11, 2023, Scilex, Oramed and Sorrento executed non-binding term sheets relating to, among other things, the Securities Transfer (as defined
below) (the “Securities Transfer Term Sheet”) (which the official committee of unsecured creditors and the official
committee of equity security holders in the Chapter 11 Cases have each signed as “Consenting Parties” thereto) and the Note
Documents (as defined below) (the “Note Term Sheet” and together with the Securities Transfer Term Sheet, the
“Scilex Term Sheets”). The Scilex Term Sheets are subject to entry into definitive documentation relating thereto.
The transactions contemplated by the Scilex Term Sheets are expected to close on or about September 19, 2023;
WHEREAS, after a hearing
before the Bankruptcy Court on September 12, 2023, the Bankruptcy Court approved, among other things, the Scilex Term Sheets and entered
the Order (I) Approving Sale of Scilex Stock to Scilex Holdings Company Free and Clear of All Liens, Claims, Interests, and Encumbrances,
(II) Conditionally Vacating the Oramed Sale Order, and (III) Granting Related Relief [Docket No. 1316] (the “Scilex Sale
Order”);
WHEREAS, pursuant to
the Securities Transfer Term Sheet, the parties to the Securities Transfer Term Sheet agreed that Scilex would acquire all of the Scilex
Common Shares owned by Sorrento (other than Scilex Common Shares held in abeyance by Sorrento on behalf of certain warrantholders of Sorrento)
(the “Common Transfer Shares”), (ii) all of the Scilex Preferred Shares owned by Sorrento (the “Preferred
Transfer Shares”) and (iii) all of the warrants for the purchase of shares of Scilex common stock owned by Sorrento (the
“Transfer Warrants”, and together with the Common Transfer Shares and the Preferred Transfer Shares, the “Transfer
Securities”) (collectively, the “Securities Transfer”) for an aggregate consideration of $110
million, payable (i) by means of Scilex’s assumption of the Debtors’ DIP Facility Obligations (the “Senior DIP
Assumption”), and (ii) by such other consideration as set forth in the Securities Transfer Term Sheet;
WHEREAS, in connection
with the Senior DIP Assumption, Scilex and Oramed will enter into certain note documents, including, without limitation, a securities
purchase agreement (the “Securities Purchase Agreement”), senior secured promissory note and certain security
documents (together with the Securities Purchase Agreement, the “Note Documents”), which will amend and restate
in their entirety the Loan Documents; and
WHEREAS, in connection
with this Agreement and the Note Documents, contemporaneously with this Agreement, Sorrento and Oramed have entered into that certain
Mutual Termination and Release Agreement in respect of that certain Stock Purchase Agreement, dated as of August 7, 2023 (the “SPA
Termination”), by and between Sorrento and Oramed.
NOW, THEREFORE, in
consideration of the mutual agreements contained herein, and good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows:
1.
Representations by the Debtors and Oramed. The Debtors and Oramed each hereby represents and warrants that (i) as
of the Effective Date, the aggregate outstanding amount of all Obligations under DIP Loan Agreement and all other Loan Documents is $101,875,000,
comprised of $100,000,000 principal, $875,000 accrued and unpaid interest and $1,000,000 fees and expenses payable under the DIP Loan
Agreement and all other Loan Documents, and (ii) there are no offsets, counterclaims or defenses against the repayment of the DIP Facility
Obligations as of the Effective Date.
2.
Senior DIP Assumption. Effective upon execution and delivery of the Note Documents and the SPA Termination by the
parties thereto:
(a)
the Debtors hereby irrevocably assign and transfer to Scilex all of their rights, title and interests and duties, liabilities and
obligations under the DIP Loan Agreement and the other Loan Documents;
(b)
Scilex hereby irrevocably and unconditionally accepts such assignment and assumes such rights, title and interests and assumes
such duties, liabilities and obligations from the Debtors, including without limitation, any claims, liabilities or obligations arising
from any failure of the Debtors to perform any of their covenants, agreements, commitments and/or obligations to be performed prior to
the date hereof under the DIP Loan Agreement and the other Loan Documents; provided, however, that such indebtedness shall
be governed by the Note Documents, which amend, restate and replace in their entirety the DIP Loan Agreement and the other Loan Documents;
(c)
Oramed consents to the assignment and assumption described in Sections 2(a) and 2(b);
(d)
the parties hereto hereby agree that the Note Documents shall amend, restate and replace in their entirety the DIP Loan Agreement
and the other Loan Documents; and
(e)
the facility evidenced by the Note Documents shall not constitute a debtor-in-possession credit facility in the Chapter 11 Cases.
3.
Releases. Effective upon execution and delivery of the Note Documents and the SPA Termination by the parties thereto,
but without further action on the part of any party:
(a)
Release of Debtors. Oramed hereby releases and discharges the Debtors from any and all obligations and liabilities
arising with respect to or relating to the DIP Loan Agreement and the other Loan Documents and agrees that the Obligations of the Debtors
thereunder shall be automatically terminated and the Debtors shall be forever released and discharged and (b) any and all security interests,
pledges, liens and other interests in favor of Oramed in the Debtor’s assets shall be forever released and discharged. Oramed hereby
agrees that it shall promptly execute and deliver such additional documents and shall provide additional information as the Debtors may
deem necessary or reasonably appropriate in order to evidence or otherwise give public notice of this release.
(b)
Mutual Release. Without limiting the foregoing, Oramed, Scilex, and the Debtors agree to the mutual releases in accordance
with, and to the fullest extent set forth in the Scilex Sale Order.
(c)
Waiver of Section 1542. All parties providing releases pursuant to this Agreement expressly and voluntarily waive
Section 1542 of the California Civil Code, or any similar, comparable or equivalent provision of the statutory or non-statutory law of
California or any other jurisdiction, and expressly consents that this Agreement shall be given full force and effect according to each
and all of its express terms and provisions, including those relating to unknown and unsuspected claims, if any. Section 1542 provides:
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS
THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT,
IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”
4.
Authority; Valid Existence. Each of the parties hereto represents and warrants to each other party hereto that: (i)
it has duly executed and delivered this Agreement and it has all requisite corporate power and authority to execute, and deliver and perform
its obligations under, this Agreement; (ii) its entrance into this Agreement has been duly authorized by all necessary corporate action
on the part of such party, and; (iii) this Agreement constitutes the legal, valid,
and binding obligation of such party, enforceable against it such party
accordance with its terms; and (iv) it is duly organized and validly existing under the laws of Delaware.
5.
Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their
respective successors and assigns, including, without limitation, with respect to the Debtors, any trustee or other estate representative
appointed in the Chapter 11 Cases or any successor case (including any cases under Chapter 7 of the Bankruptcy Code).
6.
Severability. In the event that any one or more of the provisions contained in this Agreement shall be held to be
invalid, illegal, or unenforceable in any respect, the validity, legality or enforceability of the remaining provisions contained herein
shall not, in any way, be affected or impaired.
7.
Amendments. This Agreement may be modified with (and only with) the written consent of the each of the parties hereto.
8.
Governing Law; Waiver of Jury Trial. This Agreement shall be construed, interpreted and enforced under and pursuant
to the laws of the State of New York, without regard to principles of conflict of laws. All actions and proceedings arising out of or
relating to this Agreement shall be heard and determined exclusively in the United States Bankruptcy Court for the Southern District of
Texas, and the parties hereto hereby irrevocably submit to the exclusive jurisdiction of such court in any such action or proceeding and
irrevocably waive the defense of an inconvenient forum to the maintenance of any such action or proceeding; provided, however,
that, if the Bankruptcy Case is closed, any action, claim, suit or proceeding arising out of, based upon, or relating to this Agreement
or the transactions contemplated herby shall be heard and determined exclusively in any state or federal court located in New York County,
New York. Each party agrees that a final, non-appealable judgment in any such action or proceeding shall be conclusive and may be enforced
in other jurisdictions by suit on the judgment or in any other manner provided by law. Each party hereto irrevocably waives any objection,
including any objection to the laying of venue or based on the grounds of forum non conveniens, which it may now or hereafter have
to the bringing of any action or proceeding in such jurisdiction in respect of this Agreement or any other document related hereto. EACH
PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION
DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
9.
Counterparts; Electronic Transmission. This Agreement may be executed with counterpart signature pages or in one
or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
Counterpart signature pages or counterparts of this Agreement may be executed and delivered by electronic means (including in .pdf format
sent by electronic mail) and other electronic signatures, and the receiving party may rely on the receipt of such document so executed
and delivered by electronic means as if the original had been received.
10.
Valuation.
(a)
For purposes of this Agreement, “Warrants” means, collectively: (i) the warrant to purchase common stock
(and any other class of securities into which such securities may hereafter be reclassified or changed) of Scilex, par value $0.0001 per
share (“Common Stock”), delivered to Oramed on the Effective Date, which warrant shall have an exercise price
of $0.01 per share of Common Stock issuable upon exercise thereof, and be exercisable for 4,500,000 shares of Common Stock; (ii) the warrants
to purchase Common Stock delivered to Oramed on the Effective Date, which warrants shall have an exercise price of $0.01 per share of
Common Stock issuable upon exercise thereof, and be exercisable for an aggregate number of up to 8,500,000 shares of Common Stock; and
(iii) the warrant to purchase Common Stock transferred to Oramed on the Effective Date, which warrant has an exercise price of $11.50
per share of Common Stock issuable upon exercise thereof, and is exercisable for 4,000,000 shares of Common Stock.
(b)
Within twenty (20) Business Days (as that term is defined in the Securities Purchase Agreement) after the Effective Date, Oramed
will prepare and deliver to the Debtors and Scilex a preliminary valuation statement (the “Proposed Valuation Statement”)
setting forth its calculation of the valuation of the Warrants. Each of the Debtors and Scilex shall have ten (10) Business Days thereafter
to dispute such Proposed Valuation Statement, with any failure to dispute during this time deemed an acceptance of such Proposed Valuation
Statement as a “Final Valuation Statement.” In the event of any dispute regarding the Proposed Valuation Statement,
Oramed, the Debtors and Scilex shall negotiate in good faith to resolve such dispute; provided, however, that if such parties
are unable to resolve any such dispute within fifteen (15) Business Days after a notification of dispute to Oramed, the parties shall
use reasonable discretion to select a nationally-recognized expert in valuing assets of this type (with each of Oramed, the Debtors and
Scilex bearing one-third of the associated fees and expenses). The selected expert resolution will be the Final Valuation Statement and
shall be deemed final and binding as to each of Oramed, the Debtors and Scilex. Except as specifically required pursuant to a final “determination”
within the meaning of Section 1313(a) of the Code, the parties shall report and file Tax Returns in all respects and for all purposes
in a manner consistent with the Final Valuation Statement, and shall not take any position before any Governmental Authority that is in
any way inconsistent with the Final Valuation Statement.
THE REMAINDER OF THIS PAGE IS INTENTIONALLY
LEFT BLANK;
SIGNATURE PAGES FOLLOWS
IN WITNESS WHEREOF, Scilex,
Oramed and the Debtors, by their respective duly authorized representatives, have executed and delivered this Agreement as of the day
and year first above written.
|
SCILEX HOLDING COMPANY, |
|
a Delaware corporation |
|
|
|
By: |
/s/ Jaisim Shah |
|
Name: |
Jaisim Shah |
|
Title: |
Chief Executive Officer and President |
[Signature pages continue]
|
ORAMED PHARMACEUTICALS INC., |
|
a Delaware corporation |
|
|
|
By: |
/s/ Nadav Kiron |
|
Name: |
Nadav Kiron |
|
Title: |
Chief Executive Officer |
[Signature pages continue]
SORRENTO THERAPEUTICS, INC.,
a Delaware corporation |
|
|
|
By: |
/s/
Mohsin Y. Meghji |
|
Name: Mohsin Y. Meghji Title:
Chief Restructuring Officer |
|
|
|
SCINTILLA PHARMACEUTICALS, INC.,
a Delaware corporation |
|
|
|
By: |
/s/ Mohsin Y.
Meghji |
|
Name: Mohsin Y. Meghji Title:
Chief Restructuring Officer |
|
EXHIBIT 99.1
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL
INFORMATION
On September 21, 2023, Sorrento
Therapeutics, Inc. (the “Company” or “Sorrento”) entered into a stock purchase agreement with Scilex Holding Company
(“Scilex”) whereby Scilex acquired (i) all of the shares of Scilex common stock owned by Sorrento (other than 1,917,210 shares
of Scilex common stock held in abeyance by Sorrento on behalf of certain warrant holders of Sorrento) (the “Common Transfer Shares”),
(ii) all of the shares of Series A preferred stock of Scilex owned by Sorrento (the “Preferred Transfer Shares”) and (iii)
all of the warrants for the purchase of shares of Scilex common stock owned by Sorrento (the “Transfer Warrants” and, together
with the Common Transfer Shares and the Preferred Transfer Shares, the “Transfer Securities”; and such transfers, collectively,
the “Securities Transfer”) for aggregate consideration consisting of: (i) $110 million (inclusive of the assumption by Scilex
of approximately $100 million of debt under the Company’s non-amortizing super-priority senior secured debtor-in-possession term
loan facility (the “Senior DIP Facility”)); (ii) the assumption by Scilex of certain obligations of Sorrento for legal fees
and expenses in the amount of approximately $12.25 million; and (iii) a credit bid of approximately $23 million, representing all amounts
owed to Scilex under the Company’s non-amortizing super-priority junior secured term loan facility (the “Junior DIP Facility”).
As a result of the Securities Transfer, the Company no longer has a controlling interest
over Scilex. Consequently, Scilex will be deconsolidated from the Company’s financial statements and will be presented as discontinued
operations.
The following unaudited pro forma condensed consolidated financial
information (the “pro forma financial information”) is intended to illustrate how the Securities Transfer and related transactions,
including the assumption by Scilex of the Senior DIP Facility and the credit bid of the Junior DIP Facility (such transactions, collectively,
the “Transactions”), would have affected the historical financial statements of Sorrento. The pro forma financial information
has been prepared in accordance with Article 11 of Regulation S-X and was derived, in part, from the Company’s historical condensed
consolidated financial statements and is being presented to give effect to the Transactions and the deconsolidation of Scilex from Sorrento’s
consolidated financial statements (the “Deconsolidation”). The Company’s accounting and financial reporting in these
unaudited pro forma financial statements is based on its preliminary assessment of the appropriate application of U.S. generally accepted
accounting principles (“GAAP”). The final application of GAAP to the Transactions and
the Deconsolidation may differ from what is presented in these unaudited pro forma financial statements.
The preparation of the pro forma financial information required management
to make certain assumptions and estimates based upon available information and certain assumptions that the Company believes are reasonable
under the circumstances. The unaudited pro forma condensed consolidated balance sheet as of June 30, 2023 gives effect to the Transactions
and the Deconsolidation as if they were completed as of that date. The unaudited pro forma condensed consolidated statements of operations
for the six months ended June 30, 2023 and for year ended December 31, 2022 give effect to the Transactions and the Deconsolidation as
if they were completed on January 1, 2022.
The pro forma adjustments are described in the accompanying notes and
are based upon and derived from information and assumptions available at the time of the filing of the Current Report on Form 8-K to which
this pro forma financial information is attached.
The accompanying pro forma financial information should be read together
with:
· | the accompanying notes to the pro forma financial information; |
· | the Company’s historical consolidated financial statements and the accompanying notes included in the Company’s Quarterly
Report on Form 10-Q for the three and six months ended June 30, 2023 filed with the Securities and Exchange Commission (the “SEC”)
on August 14, 2023; and |
· | the Company’s audited historical consolidated financial statements and the accompanying notes included in the Company’s
Annual Report on Form 10-K as of and for the year ended December 31, 2022 filed with the SEC on March 16, 2023. |
The pro forma financial information is provided for illustrative purposes
only and does not purport to represent what the actual consolidated results of operations of the Company would have been had the Transactions
and the Deconsolidation occurred on the dates assumed, nor are they necessarily indicative of future consolidated results of operations.
The unaudited pro forma condensed consolidated statements of operations do not reflect the costs of any disintegration activities or benefits
that may result from realization of future cost savings from the Transactions or the Deconsolidation.
SORRENTO THERAPEUTICS, INC.
(DEBTOR-IN-POSSESSION)
PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
AS OF JUNE 30, 2023
(In thousands, except for share amounts; unaudited)
| |
| | |
Transaction | | |
| |
| |
| |
| | |
Accounting | | |
| |
| |
ASSETS | |
As Reported | | |
Adjustments | | |
Note 2 | |
Pro Forma | |
Current assets: | |
| | | |
| | | |
| |
| | |
Cash and cash equivalents | |
$ | 69,749 | | |
$ | (2,497 | ) | |
(a), (b), (e) | |
$ | 67,252 | |
Marketable investments | |
| 10,886 | | |
| 3,355 | | |
(g) | |
| 14,241 | |
Accounts receivables, net | |
| 32,725 | | |
| (27,568 | ) | |
(b) | |
| 5,157 | |
Inventory | |
| 9,651 | | |
| (3,110 | ) | |
(b) | |
| 6,541 | |
Prepaid expenses | |
| 5,222 | | |
| (4,447 | ) | |
(b) | |
| 775 | |
Other current assets | |
| 4,878 | | |
| 1,043 | | |
(b) | |
| 5,921 | |
Total current assets | |
| 133,111 | | |
| (33,224 | ) | |
| |
| 99,887 | |
Property and equipment, net | |
| 53,237 | | |
| (760 | ) | |
(b) | |
| 52,477 | |
Operating lease right-of-use assets | |
| 53,408 | | |
| (3,294 | ) | |
(b) | |
| 50,114 | |
Intangibles, net | |
| 122,283 | | |
| (38,538 | ) | |
(b) | |
| 83,745 | |
Goodwill | |
| 80,269 | | |
| (13,481 | ) | |
(b) | |
| 66,788 | |
Equity investments | |
| 12,008 | | |
| — | | |
| |
| 12,008 | |
Other assets, net | |
| 2,376 | | |
| (1,144 | ) | |
(b) | |
| 1,232 | |
Total assets | |
| 456,692 | | |
| (90,441 | ) | |
| |
| 366,251 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |
| | | |
| | | |
| |
| | |
Current liabilities: | |
| | | |
| | | |
| |
| | |
Accounts payable | |
$ | 18,554 | | |
| (11,412 | ) | |
(b) | |
| 7,142 | |
Accrued payroll and related benefits | |
| 6,964 | | |
| (2,752 | ) | |
(b) | |
| 4,212 | |
Accrued expenses and other current liabilities | |
| 91,924 | | |
| (57,978 | ) | |
(a), (b), (e) | |
| 33,946 | |
Accrued legal settlements | |
| — | | |
| — | | |
| |
| — | |
Current portion of deferred revenue | |
| 256 | | |
| — | | |
| |
| 256 | |
Current portion of operating lease liabilities | |
| 13,051 | | |
| (776 | ) | |
(b) | |
| 12,275 | |
Current portion of contingent consideration | |
| 397 | | |
| — | | |
| |
| 397 | |
Acquisition consideration | |
| 515 | | |
| (515 | ) | |
(b) | |
| — | |
Income tax payable | |
| 12,926 | | |
| — | | |
| |
| 12,926 | |
Current portion of debt | |
| 120,362 | | |
| (109,356 | ) | |
(b), (e) | |
| 11,006 | |
Total current liabilities | |
| 264,949 | | |
| (182,789 | ) | |
| |
| 82,160 | |
Long-term debt, net of discount | |
| 21,741 | | |
| — | | |
| |
| 21,741 | |
Deferred tax liabilities, net | |
| 238 | | |
| — | | |
| |
| 238 | |
Deferred revenue | |
| 896 | | |
| — | | |
| |
| 896 | |
Derivative liabilities | |
| 1,600 | | |
| (1,600 | ) | |
(b) | |
| 0 | |
Operating lease liabilities | |
| 52,446 | | |
| (2,594 | ) | |
(b) | |
| 49,852 | |
Contingent consideration | |
| 550 | | |
| — | | |
| |
| 550 | |
Other long-term liabilities | |
| 3,305 | | |
| (3,305 | ) | |
(b) | |
| — | |
Total liabilities not subject to compromise | |
| 345,725 | | |
| (190,288 | ) | |
| |
| 155,437 | |
Liabilities subject to compromise | |
| 308,923 | | |
| (12,250) | | |
| |
| 296,673 | |
Total liabilities | |
| 654,648 | | |
| (202,538 | ) | |
| |
| 452,110 | |
Equity (Deficit): | |
| | | |
| | | |
| |
| | |
Sorrento Therapeutics, Inc. equity (deficit) | |
| | | |
| | | |
| |
| | |
Common stock | |
| 55 | | |
| — | | |
| |
| 55 | |
Additional paid-in capital | |
| 2,036,331 | | |
| — | | |
| |
| 2,036,331 | |
Accumulated other comprehensive income | |
| 2,240 | | |
| — | | |
| |
| 2,240 | |
Accumulated deficit | |
| (2,194,275 | ) | |
| 116,628 | | |
(d) | |
| (2,077,647 | ) |
Treasury stock | |
| (49,464 | ) | |
| — | | |
| |
| (49,464 | ) |
Total Sorrento Therapeutics, Inc. stockholders’ deficit | |
| (205,113 | ) | |
| 116,628 | | |
| |
| (88,485 | ) |
Noncontrolling interests | |
| 7,157 | | |
| (4,531 | ) | |
(c) | |
| 2,626 | |
Total deficit | |
| (197,956 | ) | |
| 112,097 | | |
| |
| (85,859 | ) |
Total liabilities and stockholders’ equity (deficit) | |
$ | 456,692 | | |
$ | (90,441 | ) | |
| |
$ | 366,251 | |
See accompanying notes to the pro forma financial information.
SORRENTO THERAPEUTICS, INC.
(DEBTOR-IN-POSSESSION)
PRO FORMA CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS
FOR THE SIX MONTHS ENDED JUNE 30, 2023
(In thousands, except for per share amounts;
unaudited)
| |
| | |
Transaction | | |
| | |
| |
| |
| | |
Accounting | | |
| | |
| |
| |
As Reported | | |
Adjustments | | |
Note 2 | | |
Pro Forma | |
Revenues: | |
| | |
| | |
| | |
| |
Net product revenues | |
$ | 23,202 | | |
$ | (23,164 | ) | |
| (f) | | |
$ | 38 | |
Service revenues | |
| 8,074 | | |
| — | | |
| | | |
| 8,074 | |
Total revenues | |
| 31,276 | | |
| (23,164 | ) | |
| | | |
| 8,112 | |
Operating costs and expenses: | |
| | | |
| | | |
| | | |
| | |
Cost of products sold | |
| 10,445 | | |
| (7,768 | ) | |
| (f) | | |
| 2,677 | |
Cost of services | |
| 3,193 | | |
| — | | |
| | | |
| 3,193 | |
Research and development | |
| 77,076 | | |
| (5,940 | ) | |
| (f) | | |
| 71,136 | |
Selling, general and administrative | |
| 103,920 | | |
| (55,690 | ) | |
| (f) | | |
| 48,230 | |
Intangible amortization | |
| 2,254 | | |
| (2,053 | ) | |
| (f) | | |
| 201 | |
Increase (decrease) on contingent consideration | |
| 3,800 | | |
| — | | |
| | | |
| 3,800 | |
Loss on impairment of intangible assets | |
| 12,366 | | |
| — | | |
| | | |
| 12,366 | |
Legal settlement | |
| 1,797 | | |
| — | | |
| | | |
| 1,797 | |
Total operating costs and expenses | |
| 214,851 | | |
| (71,451 | ) | |
| | | |
| 143,400 | |
Loss from operations | |
| (183,575 | ) | |
| 48,287 | | |
| | | |
| (135,288 | ) |
(Loss) gain on derivative liabilities | |
| (1,300 | ) | |
| 1,300 | | |
| (f) | | |
| — | |
Loss on marketable and equity investments | |
| (15,460 | ) | |
| 3,029 | | |
| (h) | | |
| (12,431 | ) |
Loss on debt extinguishment, net | |
| (40 | ) | |
| — | | |
| | | |
| (40 | ) |
Loss (gain) on foreign currency exchange | |
| 153 | | |
| 23 | | |
| (f) | | |
| 176 | |
Interest expense, net | |
| (3,800 | ) | |
| 4 | | |
| (f) | | |
| (3,796 | ) |
Other loss | |
| (4,299 | ) | |
| 3,748 | | |
| (f) | | |
| (551 | ) |
Reorganization items, net | |
| (42,235 | ) | |
| — | | |
| | | |
| (42,235 | ) |
Loss before income tax | |
| (250,556 | ) | |
| 56,391 | | |
| | | |
| (194,165 | ) |
Income tax expense (benefit) | |
| 12,139 | | |
| (5 | ) | |
| (f) | | |
| 12,134 | |
Gain (loss) on equity method investments | |
| (368 | ) | |
| — | | |
| | | |
| (368 | ) |
Net loss | |
| (263,063 | ) | |
| 56,396 | | |
| | | |
| (206,667 | ) |
Net loss attributable to noncontrolling interests | |
| (28,334 | ) | |
| 27,419 | | |
| (c) | | |
| (915 | ) |
Net loss attributable to Sorrento | |
$ | (234,729 | ) | |
$ | 28,977 | | |
| | | |
$ | (205,752 | ) |
Net loss per share - basic per share attributable to Sorrento | |
$ | (0.43 | ) | |
| | | |
| | | |
$ | (0.38 | ) |
Net loss per share - diluted per share attributable to Sorrento | |
$ | (0.43 | ) | |
| | | |
| | | |
$ | (0.38 | ) |
Weighted-average shares used during period - basic shares attributable to Sorrento | |
| 547,232 | | |
| | | |
| | | |
| 547,232 | |
Weighted-average shares used during period - diluted shares attributable to Sorrento | |
| 547,232 | | |
| | | |
| | | |
| 547,232 | |
See accompanying notes to the pro forma financial information.
SORRENTO THERAPEUTICS, INC.
PRO FORMA CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 2022
(In thousands, except for per share amounts;
unaudited)
| |
| | |
Transaction | | |
| | |
| |
| |
| | |
Accounting | | |
| | |
| |
| |
As Reported | | |
Adjustments | | |
Note 2 | | |
Pro Forma | |
Revenue: | |
| | |
| | |
| | |
| |
Net product revenues | |
$ | 44,996 | | |
$ | (38,034 | ) | |
| (f) | | |
$ | 6,962 | |
Service revenues | |
| 17,843 | | |
| — | | |
| | | |
| 17,843 | |
Total revenues | |
| 62,839 | | |
| (38,034 | ) | |
| | | |
| 24,805 | |
Operating costs and expenses: | |
| | | |
| — | | |
| | | |
| — | |
Cost of product sold | |
| 28,913 | | |
| (10,797 | ) | |
| (f) | | |
| 18,116 | |
Cost of services | |
| 4,539 | | |
| — | | |
| | | |
| 4,539 | |
Research and development | |
| 221,226 | | |
| (9,054 | ) | |
| (f) | | |
| 212,172 | |
Acquired in-process research and development | |
| 12,272 | | |
| — | | |
| | | |
| 12,272 | |
Selling, general and administrative | |
| 182,337 | | |
| (64,895 | ) | |
| (f) | | |
| 117,442 | |
Intangible amortization | |
| 4,325 | | |
| (3,922 | ) | |
| (f) | | |
| 403 | |
(Decrease) increase on contingent consideration | |
| (75,400 | ) | |
| — | | |
| | | |
| (75,400 | ) |
Loss on impairment of intangible assets | |
| 124,190 | | |
| — | | |
| | | |
| 124,190 | |
Legal settlements, net | |
| 64,752 | | |
| — | | |
| | | |
| 64,752 | |
Total operating costs and expenses | |
| 567,154 | | |
| (88,668 | ) | |
| | | |
| 478,486 | |
Loss from operations | |
| (504,315 | ) | |
| 50,634 | | |
| | | |
| (453,681 | ) |
Gain (loss) on derivative liabilities | |
| 7,316 | | |
| (7,316 | ) | |
| (f) | | |
| — | |
Loss on marketable and equity investments | |
| (83,919 | ) | |
| (11,618 | ) | |
| (h) | | |
| (95,537 | ) |
Gain (loss) on debt extinguishment | |
| 27,009 | | |
| (28,634 | ) | |
| (f) | | |
| (1,625 | ) |
Interest expense, net | |
| (8,574 | ) | |
| 8,500 | | |
| (f) | | |
| (74 | ) |
Other income (loss) | |
| 736 | | |
| 455 | | |
| (f) | | |
| 1,191 | |
Loss before income tax | |
| (561,747 | ) | |
| 12,021 | | |
| | | |
| (549,726 | ) |
Income tax benefit | |
| (2,416 | ) | |
| (4 | ) | |
| (f) | | |
| (2,420 | ) |
Loss on equity method investments | |
| (18,426 | ) | |
| — | | |
| | | |
| (18,426 | ) |
Net loss | |
| (577,757 | ) | |
| 12,025 | | |
| | | |
| (565,732 | ) |
Net loss attributable to noncontrolling interests | |
| (4,914 | ) | |
| 767 | | |
| (c) | | |
| (4,147 | ) |
Net loss attributable to Sorrento | |
$ | (572,843 | ) | |
$ | 11,258 | | |
| | | |
$ | (561,585 | ) |
Net loss per share - basic per share attributable to Sorrento | |
$ | (1.37 | ) | |
| | | |
| | | |
$ | (1.34 | ) |
Net loss per share - diluted per share attributable to Sorrento | |
$ | (1.37 | ) | |
| | | |
| | | |
$ | (1.34 | ) |
Weighted-average shares outstanding during period - basic shares attributable to Sorrento | |
| 419,315 | | |
| | | |
| | | |
| 419,315 | |
Weighted-average shares outstanding during period - diluted shares attributable to Sorrento | |
| 419,315 | | |
| | | |
| | | |
| 419,315 | |
See accompanying notes to the pro forma financial information.
SORRENTO THERAPEUTICS, INC.
NOTES TO UNAUDITED CONDENSED PRO FORMA CONSOLIDATED
FINANCIAL INFORMATION
NOTE 1 – BASIS OF PRO FORMA PRESENTATION
The pro forma financial information is prepared in accordance with
Article 11 of Regulation S-X. The pro forma adjustments are described in the accompanying notes and are based upon and derived from information
and assumptions available at the time of the filing of the Current Report on Form 8-K to which this pro forma financial information is
attached.
The pro forma financial information is based on financial statements
prepared in accordance with GAAP, which is subject to change and interpretation. The pro forma financial information is based on and derived
from the Company’s historical consolidated financial statements, adjusted for certain transaction accounting adjustments. Actual
adjustments, however, may differ materially from the information presented. The pro forma adjustments do not include allocations of corporate
costs, as those are not directly attributable to the Transactions or the Deconsolidation. The pro forma adjustments also do not include
management adjustments to reflect any potential dis-synergy costs or benefits that may result from realization of future cost savings
that may occur in connection with the Transactions or the Deconsolidation as management does not believe presenting such adjustments would
enhance an understanding of the pro forma effects thereof. In addition, the pro forma financial information is based upon available information
and assumptions that management considers to be reasonable, and such assumptions have been made solely for purposes of developing such
pro forma financial information for illustrative purposes in compliance with the disclosure requirements of the SEC. The pro forma financial
information is not necessarily indicative of what the financial position or statements of operations results would have actually been
had the Transactions or the Deconsolidation occurred on the dates indicated. In addition, the pro forma financial information should not
be considered to be indicative of the Company’s future consolidated financial performance and statement of operations results.
The Securities Transfer constituted a
significant disposition for purposes of Item 2.01 of Form 8-K. As a result of the Securities Transfer, the Company has concluded
that it will no longer control Scilex and, therefore, Scilex will be deconsolidated from the Company’s consolidated financial statements
effective as of the date of the consummation of the Securities Transfer. Based upon the magnitude of the
disposition and because the Company is exiting an entire business segment, the disposition represents a significant strategic shift that
will have a material effect on the Company’s operations and financial results. Accordingly, the Securities Transfer meets the definition
of a discontinued operation, as defined by Accounting Standards Codification 205-20 – Discontinued Operations, which has
not yet been retrospectively applied in the historical financial statements.
The pro forma financial information reflects the Company’s condensed
consolidated balance sheet as of June 30, 2023 and condensed consolidated statements of operations for the six months ended June 30, 2023
and the year ended December 31, 2022.
NOTE 2 – TRANSACTION ACCOUNTING ADJUSTMENTS
The following adjustments have been reflected in the pro forma financial
information for the following related to the Transactions and the Deconsolidation:
| (a) | Adjustment to includes the $110.0 million of consideration for the Securities Transfer as well as the assumption by Scilex of a $12.25
million liability related to legal fees. The consideration reflected in the pro forma consolidated balance sheet as of June 30, 2023 does
not include the credit bid of all amounts owed under the Junior DIP Facility as the facility amount was not drawn until July 2023. See
further discussions below. |
| (b) | Adjustments to reflect the elimination of assets and liabilities attributable to Scilex. The Company’s related party receivables
from Scilex amounting to $1.0 million which was eliminated in the Company’s condensed consolidated balance sheet as of June 30,
2023 has been reflected as other current assets in the pro forma condensed consolidated balance sheet. |
| (c) | Adjustments to reflect the derecognition of non-controlling interest related to Scilex. |
| (d) | Adjustments to reflect the book gain arising from the Securities Transfer. As described above, the pro forma statements of operations
present the Company’s results as if the Transactions and the Deconsolidation had occurred on January 1, 2022. Any estimated gain
or loss related to the discontinued operations and the Transactions has been excluded from the unaudited pro forma condensed consolidated
statement of operations for the year ended December 31, 2022 or the six months ended June 30, 2023 as this amount pertains to discontinued
operations and does not reflect the impact on income from continuing operations. |
| (e) | Adjustments to reflect the derecognition of the Senior DIP Facility amounting to $75.0 million and the related accrued exit fee amounting
to $5.25 million outstanding as of June 30, 2023. See further discussions below. |
| (f) | Adjustments to reflect the elimination of revenues and expenses attributable to Scilex. Other than the elimination of Scilex’s
income tax expense in the pro forma condensed consolidated statement of operations, there are no other pro forma income tax adjustments
reflected. The Company’s tax basis on the securities sold exceeds the purchase price by Scilex which is expected to result in the
recognition of a tax loss. Any resulting future tax benefit has not been reflected in the pro forma financial information. |
| (g) | Adjustment to reflect the value of the remaining 1,917,210 unsold Scilex common stock owned by
Sorrento. The shares are measured at fair value based on the closing price of Scilex’s
common stock on September 21, 2023. |
| (h) | Adjustments to reflect the change in value of the remaining 1,917,210 unsold Scilex common stock owned by Sorrento. |
As of June 30, 2023, the total outstanding principal balance of the
Senior DIP Facility was $75.0 million with JMB Capital Partners Lending LLC as the creditor. As of the date of the stock purchase agreement,
the total outstanding principal balance of the Senior DIP Facility was $100.0 million with Oramed Pharmaceuticals Inc. as the creditor.
As described above, the aggregate consideration for the Securities Transfer includes the assumption
by Scilex of the outstanding $100 million Senior DIP Facility, however, the unaudited pro
forma condensed consolidated balance sheet as of June 30, 2023 only reflects the derecognition of the Junior DIP Facility outstanding
as of June 30, 2023.
In July 2023, the Company entered into the Junior DIP Facility with
Scilex in an amount of (i) $20,000,000 (the “Base Amount”), plus the amount of the commitment fee and the funding fee, each
equal to 1% of the Base Amount, plus (iii) the amount of the DIP Lender Holdback (as defined in the Interim Junior DIP Order). As described
above, the purchase price for the Securities Transfer by Scilex includes a credit bid of all amounts owed by the Company to Scilex under
the Junior DIP Facility. The unaudited pro forma condensed consolidated balance sheet as of June 30, 2023 does not reflect the
Junior DIP Facility or the derecognition thereof.
The stock purchase agreement provides transition services between Sorrento
and Scilex for a period of up to 120 days following the closing date of the Securities Transfer. The pro forma condensed financial information
does not include any compensation related to the transition services as the amount cannot be reasonably estimated.
Exhibit 99.2
Sorrento Therapeutics, Inc. Announces the
Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento
Held in Scilex Holding Company
SAN DIEGO, CA. September 22, 2023 /Newswire/ -- Sorrento Therapeutics,
Inc. (OTC: SRNEQ, “Sorrento” or “Company”), a biopharmaceutical company dedicated to the development of life-saving
therapeutics to treat cancer, intractable pain, and infectious disease, announced the consummation on September 21, 2023, of the previously
announced sale to Scilex Holding Company (Nasdaq: SCLX, “Scilex”) of certain securities that Sorrento held in Scilex.
Pursuant to that certain Stock Purchase Agreement entered into on September
21, 2023, between Scilex and Sorrento, Scilex, through its wholly-owned subsidiary, acquired (i) all of the shares of Scilex common stock
owned by Sorrento (other than such shares held in abeyance by Sorrento on behalf of certain warrant holders of Sorrento), (ii) all of
the shares of Scilex preferred stock owned by Sorrento, and (iii) all of the warrants for the purchase of shares of Scilex common stock
owned by Sorrento (collectively, the “Securities Transfer”) for aggregate consideration consisting of: (i) $110 million (comprised
of cash payments of $10 million (in the aggregate) and the assumption by Scilex of the approximately $100 million senior secured term
loan facility provided by Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, “Oramed”) to Sorrento ); plus (ii) the assumption by
Scilex of certain legal fees and expenses of Sorrento in the amount of approximately $12.25 million; plus (iii) a credit bid of all amounts
owed to Scilex under the junior secured debtor-in-possession financng facility provided by Scilex to Sorrento. As a result of the Securities
Transfer, the Company no longer has a controlling interest over Scilex and Scilex ceased to be a majority-owned subsidiary of Sorrento.
Consequently, we expect Scilex will be deconsolidated from the Company’s financial statements prospectively and will be presented
as discontinued operations.
Additionally, upon the closing of the Securities Transfer, Sorrento
and Oramed mutually terminated that certain Stock Purchase Agreement (as amended, the “Oramed SPA”), dated as of August 7,
2023, between Oramed and Sorrento for the sale of Sorrento’s equity interests in Scilex to Oramed, which termination includes a
release of claims by each of the parties relating to the Oramed SPA.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage
biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.
Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms,
including key assets such as next-generation tyrosine kinase inhibitors ("TKIs"), fully human antibodies
("G-MAB™ library"), immuno-cellular therapies ("DAR-T™"), antibody-drug conjugates
("ADCs"), and oncolytic virus ("Seprehvec™"). Sorrento is also developing potential antiviral therapies
and vaccines against coronaviruses, including STI-1558 and COVI-MSC™; and diagnostic test solutions, including
COVIMARK™.
Sorrento's commitment to life-enhancing therapies for patients is also
demonstrated by our effort to advance a TRPV1 agonist, non-opioid pain management small molecule, resiniferatoxin ("RTX"). RTX
has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.
For more information visit www.sorrentotherapeutics.com.
Forward-Looking Statements
This press release and any statements made for and during any presentation
or meeting concerning the matters discussed in this press release contain forward-looking statements related to Sorrento and its subsidiaries
under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties
that could cause actual results to differ materially from those projected. Forward-looking statements generally are accompanied by words
such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,”
“seem,” “seek,” “future,” “outlook,” and similar expressions. Forward-looking statements
include statements regarding the Securities Transfer and the anticipated accounting treatment resulting from the Securities Transfer.
Risks and uncertainties that could cause
Sorrento's actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but
are not limited to risks associated with the ability of the Company to use such proceeds efficiently in support of its business; the
Company’s ability to obtain exit financing and to pursue a plan of reorganization to exit its chapter 11 bankruptcy; and those
factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly
Reports on Form 10-Q filed with the SEC in each case under the heading “Risk Factors,” and other documents of the
Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ
materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently
does not know or that the Company currently believes are immaterial that could also cause actual results to differ from those
contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release, and Sorrento undertakes no obligation to update any
forward-looking statement in this press release except as may be required by law.
Contacts:
For Sorrento Therapeutics, Inc.
Media Contact
The Levinson Group
212-202-2754
Email: sorrento@tlgcommunications.com
Website: www.sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of Sorrento
Therapeutics, Inc.
G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVI-MSC™,
COVIMARK™, Fujovee™ and Ovydso™ are trademarks of Sorrento Therapeutics, Inc.
All other trademarks are the property of their respective owners.
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Sorrento Therapeutics (CE) (USOTC:SRNEQ)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sorrento Therapeutics (CE) (USOTC:SRNEQ)
Historical Stock Chart
From Aug 2023 to Aug 2024